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Abstract 
Preterm birth is the leading cause of perinatal morbidity and mortality worldwide. 
Despite considerable efforts, prediction and prevention of preterm birth continues to 
remain a challenge for obstetricians globally. Early identification of pregnancies at 
highest risk of preterm birth may enable the implementation of therapeutic strategies 
aiming to prevent preterm birth and/or the morbidities associated with early delivery. 
Screening for spontaneous preterm birth is made more complex due to the 
heterogeneity of this condition, which has a variety of underlying aetiologies and risk 
factors. Even though spontaneous preterm birth is caused by several aetiologies, there 
appears to be a final common pathway leading to the onset of labour. There may 
therefore be value either in developing screening tools that screen for multiple 
aetiological pathways or alternatively that identify common features that develop 
before women become symptomatic with the onset of spontaneous labour. Paper I 
reviews recent research findings related to first trimester prediction and prevention of 
adverse pregnancy outcomes.  
This thesis reports a body of work related to the development of a predictive 
test for spontaneous preterm labour. Paper II is focussed on the challenges of using 
current proteomic strategies to identify and quantify novel protein markers of disease 
in serum. I carried out various optimisation strategies to resolve protein species in 
maternal serum using a refined top-down two-dimensional gel electrophoresis method 
coupled with mass spectrometry. In addition to this, a process of deep imaging using 
third separation gel electrophoresis was adapted to effectively resolve protein species 
and isoforms that would not be recognised by traditional proteomic techniques as they 
would be masked by co-migrating protein species of higher abundance.  
These techniques were applied in Paper III where they were used to identify 
protein species and post translationally modified proteoforms (phosphorylation and 
glycosylation) in first trimester maternal serum banked from cohorts of women who 
delivered spontaneously before 37 weeks’ gestation. These findings were compared to 
serum collected from a cohort of women who delivered at term (≥ 37 weeks’ 
gestation).  
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Paper IV utilised a western blot approach to determine serum concentrations 
of a select group of candidate protein species and proteoforms that were significantly 
altered in Paper II in a larger cohort of women that had delivered after spontaneous 
preterm labour (<37 weeks) compared to matched term (>37 weeks) controls. A 
variant of Vitamin D-binding protein was found to be significantly decreased in 
women who delivered < 37 weeks spontaneously.  
This work has shown that there is evidence of change in protein abundance as 
early as 11-13 weeks of gestation in women who continue on to deliver preterm after 
the spontaneous onset of labour. Further work is needed to determine the strength of 
these findings in predicting risk of preterm birth. Further work should also examine 
how novel biomarkers can be combined with established screening tools in larger 
diverse patient cohorts to validate their potential use as candidates for prediction of 
spontaneous preterm birth. 
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1.1 Background 
1.1.1 Definition of preterm birth 
The World Health Organization defines preterm birth as a livebirth that occurs before 
37 completed weeks of pregnancy (Howson, 2012). Preterm birth can be further sub-
categorised on the basis of gestational age as extremely preterm (less than 28 
completed weeks of gestation), very preterm (28 to 32 completed weeks of gestation) 
and moderate to late preterm (32 to 36 completed weeks of gestation) (Quinn et al., 
2016).  
 
1.1.2 Characterisation of preterm birth 
There are three broad clinical categories that describe preterm birth: Preterm birth may 
be medically indicated (iatrogenic), occur after preterm premature rupture of 
membranes (PPRoM) or after the spontaneous (idiopathic) onset of labour (Savitz et 
al., 1991, Meis et al., 1987). Whilst iatrogenic preterm birth is easy to identify, it is 
sometimes harder to discriminate between spontaneous preterm birth (sPTB) and 
labour that occurs secondary to PPRoM. Typically, PPRoM is defined in 
circumstances where spontaneous rupture of membranes occurs at least one hour prior 
to the onset of contractions, at less than 37 weeks’ gestation (2018) . 
 
1.1.3 Worldwide incidence and associated morbidity and mortality 
Preterm birth is the single largest direct cause of perinatal morbidity and mortality in 
the developed world and has long-term adverse consequences for health (Blencowe et 
al., 2013). Preterm neonates have higher rates of cerebral palsy, sensory deficits, 
respiratory illnesses and learning disabilities as well as long term health complications 
resulting in enormous physical and economic costs to healthcare systems as well as 
emotional and financial distress to affected families (Wu and Colford, 2000, Tronnes 
et al., 2014, Wickremasinghe et al., 2013, Kwinta and Pietrzyk, 2010, Harris et al., 
2013, Khan et al., 2015).  
Worldwide, an estimated 15 million babies are born preterm each year 
(Blencowe et al., 2012) (Figure 1.1). Preterm birth accounts for 28% of all neonatal 
deaths globally (Lawn et al., 2006b). The rate of preterm birth has been reported to 
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range from 5% - 9% of live births in some developed countries and is estimated to be 
significantly higher in developing countries (Lawn et al., 2006a). Global rates of 
preterm birth have increased over the past two decades (Davidoff et al., 2006, 
Blencowe et al., 2012, Ananth et al., 2005, MacDorman et al., 2010).  
About 30-35% of all preterm births are attributed to medically indicated 
preterm birth that occurs in the absence of PPRoM or spontaneous preterm labour 
(Ananth et al., 2005, Ananth and Vintzileos, 2006a). Medical indications relate to 
maternal complications (gestational diabetes, preeclampsia), fetal complications 
(growth restriction, multiple pregnancies, congenital anomalies, threatened fetal well-
being) and placental complications (Xue et al., 2016, Ananth and Vintzileos, 2006b). 
Cases of iatrogenic prematurity are rare and occur in instances when a baby is 
compromised and suddenly stops moving or when a woman is induced <37 weeks due 
to incorrect dating (Moutquin, 2003).  
Premature preterm rupture of membranes, usually followed by preterm 
delivery, accounts for another 30% of all preterm births (Caughey et al., 2008). 
Women of African-American race and those from lower socioeconomic populations 
are more prone to PPRoM (Shen et al., 2008). There is overwhelming evidence 
suggesting infection as the primary cause of labour in women affected by PPRoM 
(Menon and Fortunato, 2007, Goldenberg et al., 2000a, Al Riyami et al., 2013).  
About 40% of all preterm births are spontaneous or ‘idiopathic’ and are more 
common in women without any recognized risk factors (Goldenberg et al., 2008). 
Early spontaneous preterm birth (<32 weeks' gestation) is linked to increased perinatal 
mortality (Costeloe et al., 2012, Vohr et al., 2000, Ancel, 2015). Although the risk 
factors associated with sPTB vary according to gestational age and are dependent on 
various social and environmental factors, the exact cause(s) and mechanism(s) 
associated with this condition remain unknown in more than 50% of the cases 
(Menon, 2008).  
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Figure 1.1: Worldwide rates of preterm birth. Estimated preterm birth rates and 
total number of preterm births by Millennium Development Goal region. Graphical 
representation of A) 10 countries with the highest rates of preterm birth per 100 live 
births, B) 10 countries with the greatest number of preterm births. Adapted from 
Blencowe, H. et al., 2012. 
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1.1.4 Preterm birth in Australia 
There are 25,000 infants born prematurely in Australia each year ― 8.7% of 
all births - seventy each day – more than one every half hour (AIHW, 2011). Almost 
15% of all preterm babies need an increased level of care at birth (AIHW, 2016). Most 
of these preterm births (81%) belong to the late preterm birth category, followed by 
11% born extremely preterm and 10% born very preterm (AIHW, 2016).  
In the most recent published data, the average gestational age for all preterm 
birth was 33.3 weeks. The highest proportion (10.6%) of preterm births was reported 
in the Northern Territory while New South Wales had the lowest, at 7.4% of all births 
(AIHW, 2016). Among infants of Aboriginal and Torres Strait Islander mothers, 
preterm birth is a significant contributor to neonatal morbidity and mortality (AIHW, 
2016). Preterm babies need continuous high-level support and care. Therefore, they 
are more likely to be admitted to a neonatal intensive care unit (72%) compared to 
babies delivered at term (10%) or post-term (13%) (AIHW, 2016).  
Several maternal risk factors have been identified that are associated with 
preterm birth. In 2015, 14% of babies born to Aboriginal and Torres Strait Islander 
mothers were preterm, in contrast to 8.0% babies born to mothers of non-Indigenous 
origin (AIHW, 2016). 13% babies were born preterm to mothers who smoked during 
pregnancy in comparison to 8% of babies whose mothers did not smoke (AIHW, 
2016). Around 64% of twins and all other multiples were born preterm in 2015 in 
comparison to 7% of singleton babies (AIHW, 2016). 11% and 12% of preterm babies 
were born to younger (< 20) and older (≥ 40) mothers compared with 8% of babies 
with mothers aged 20–39 (AIHW, 2016). 
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1.2 Pathophysiology of preterm birth 
1.2.1 Causes and risk factors  
Preterm labour, as described by Romero, is a ‘syndrome initiated by multiple 
mechanisms, including infection or inflammation, uteroplacental ischaemia or 
haemorrhage, uterine overdistension, stress, and other immune mediated processes’ 
(Romero et al., 2006) (Figure 1.2). The exact causative mechanism is typically not 
recognized in most individual cases; but risk factors, based on maternal characteristics 
and medical history, associated with these aetiologies can be elucidated and are often 
used as a basis to explain preterm labour. These risk factors are often associated with 
an increase in systemic inflammation involved in the common pathway to sPTB (Boyle 
et al., 2017). Identification of these risk factors may also be of value in predicting a 
population at increased risk of preterm birth.  
 
1.2.1.1 Maternal Risk Factors 
The risk of preterm birth can be directly correlated to maternal characteristics, varies 
between racial and ethnic groups and increases with advanced maternal age. The 
occurrence of preterm birth in African-American women (16–18%) is higher than that 
in Caucasian women (5–9%) in the United Kingdom and this is even more noticeable 
in the United States (MacDorman, 2011, Mohamed et al., 2014). When compared to 
women of other ethnic backgrounds, African-American women are three to four times 
more likely to have a very early preterm birth (Martin et al., 2006, Burris et al., 2011). 
The rate of preterm birth is typically low in women of East Asian and Hispanic origin 
and has not significantly increased in women from South Asia including the Indian 
subcontinent (Goldenberg and Culhane, 2007). The mechanism for these disparities is 
poorly understood, and the disparities persist even after socioeconomic factors are 
taken into consideration.  
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Figure 1.2: Risk factors and pathological pathways associated with preterm birth. 
Various maternal risk factors and proposed pathways of infection, cervical disorders 
and uterine distention that result in preterm birth. 
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1.2.1.2 Socioeconomic status 
A significant socioeconomic risk factor for preterm birth is maternal smoking. Women 
who smoke cigarettes are twice as likely to deliver before 32 weeks’ gestation as non-
smoking mothers (Wisborg et al., 1996, Kyrklund-Blomberg et al., 2005). 
Programmes aimed at creating awareness to cease smoking during pregnancy have 
been found to be valuable in lowering the rate of preterm birth (Lumley et al., 2004). 
Preterm birth is strongly linked to lower levels of education, lower family income, 
access to prenatal care services and adverse neighbourhood conditions (Jansen et al., 
2009, Silveira et al., 2018, Giurgescu et al., 2012). Population based studies suggest 
an increased risk of preterm and induced preterm birth in women with low BMI prior 
to pregnancy as well as in women who are overweight and obese (Han et al., 2011, 
Cnattingius et al., 2013) (Figure 1.3). Furthermore, alcohol and drug abuse, nutritional 
status, chronic diseases (such as hypertension, diabetes mellitus), and endocrinological 
disorders have been correlated with an elevated risk of preterm birth (Velez et al., 
2008b, Xinxo et al., 2013, Catov et al., 2008, Yanit et al., 2012, Sheehan et al., 2015). 
 
1.2.1.3 Psychosocial factors 
Mothers encountering mental or social pressures during pregnancy are at a 2-fold 
increased risk of preterm birth (Lilliecreutz et al., 2016). Several investigations have 
associated stress and anxiety related to housing instability or marital hardships with 
risk of preterm delivery (El-Sayed et al., 2012). Although there is no known 
mechanism to explain the correlation of stress and risk of preterm birth, recent studies 
have suggested elevated levels of corticotrophin-releasing hormone (CRH) associated 
with stress and subsequently leading to preterm birth (Ruiz et al., 2016). During the 
third trimester of pregnancy, CRH is synthesized by the placenta and released in 
significant amounts in the maternal circulations (Sandman and Glynn, 2009). It has 
been labelled as a ‘master stress hormone’ crucial to maintain pregnancy and fetal 
development (Ellman et al., 2008). Similarly, high levels of C-reactive protein (CRP), 
an indicator of inflammation, involved in the innate immune response has been 
reported in women exposed to stressful conditions (Sproston and Ashworth, 2018). 
Together, these findings suggest possible roles of these stress related molecules in 
systemic inflammation pathways leading to preterm birth.  
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Figure 1.3: Forest plot showing studies reporting the odds ratio for preterm birth 
related to obesity.  
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1.2.1.4 Pregnancy characteristics 
Pregnancy characteristics such as previous abortion, and pregnancies resulting from 
assisted reproductive treatment (ART) are important factors that predispose a woman 
to preterm birth (Freak-Poli et al., 2009, Ancel et al., 2004, Cavoretto et al., 2018) 
(Figure 1.4). Likewise, studies have shown a greater risk of preterm delivery 
(spontaneous and induced) in women undergoing invasive diagnostic procedures such 
as genetic amniocentesis (Medda et al., 2003).  
 Preterm birth is highly prevalent in multiple gestations, accounting for 15-20% 
of preterm births (Fuchs and Senat, 2016). Almost 60% of twins are born premature 
(Fuchs and Senat, 2016, National Collaborating Centre for and Children's, 2011). 
Nearly 40% of twins will be delivered spontaneously or their pregnancies will be 
interrupted by PPRoM <37 weeks’ gestation, with others having an indicated preterm 
delivery due to maternal or fetal complications. A report from the Australian Institute 
of Health and Welfare states that twins and multiple gestations comprise 64% of 
preterm births as of 2015 (AIHW, 2017).  
Women with pregnancy intervals of less than six months are at a two-fold 
greater risk of delivering prematurely in their following pregnancy (Smith et al., 2003). 
There is consistent evidence that having a previous sPTB is a strong predicting factor 
for recurrence in consequent pregnancies (Iams et al., 1998, Ekwo and Moawad, 1998, 
Kristensen et al., 1995). There is insufficient research to explain the underlying 
mechanism(s); a potential theory is that the uterus and uterine environment requires 
time to return to its quiescence state (Kota et al., 2013). Another possible theory is that 
a short pregnancy interval does not allow enough time to replenish essential vitamins 
and minerals that are depleted during the previous pregnancy (Gernand et al., 2016).  
 
1.2.1.5 Obstetric complications 
Uterine over-distension appears to play a significant role in initiating preterm labour 
in women with multiple gestations, polyhydramnios, and macrosomia, but the 
pathophysiology is yet not clearly understood (Many et al., 1996, Adams Waldorf et 
al., 2015) . An increased risk of preterm birth is often associated with vaginal bleeding 
due to placental abruption or praevia (Erez et al., 2012). However, bleeding 
independent of either placental abruption or praevia has also been linked with 
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consequent preterm birth. Women with cervical disorders such as cervical 
intraepithelial neoplasia have a greater risk for prematurity (Danhof et al., 2015, 
Kyrgiou et al., 2017). Additionally, local cervical treatment (e.g. large loop excision 
of transformation zone procedure) and maternal abdominal surgery predispose women 
to preterm delivery (Sadler et al., 2004, Jin et al., 2014) (Figure 1.5). 
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Figure 1.4: Forest plot showing studies reporting the odds ratio for preterm birth 
related to use of assisted reproductive technologies. 
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Figure 1.5: Forest plot showing studies reporting risk ratio for preterm birth in women 
treated with large loop excision of transformation zone versus untreated women 
(Kyrgiou et al., 2016).  
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1.2.1.6 Cervical insufficiency 
During a normal pregnancy, the cervix remains firm, long and closed (Myers et al., 
2015). The cervix shortens, softens and dilates as labour approaches (Gravett et al., 
2010). Cervical insufficiency occurs when the cervix shortens and dilates before term 
either due to a short cervix or when there is increasing pressure on the cervix due to 
increasing weight of the baby as the pregnancy advances (Vink and Feltovich, 2016). 
Ultrasound assessments of the cervix have confirmed cervical shortening as a risk 
factor for preterm delivery, proving to be a valued clinical tool in asymptomatic 
women and in those presenting with contractions. A cervical length of less than 25 mm 
during the second trimester of pregnancy is used clinically as a reliable predictor of 
preterm birth in the asymptomatic population (McIntosh et al., 2016, Celik et al., 
2008). A short cervix is directly proportional to higher risk of preterm birth (Figure 
1.6). Some preterm births are caused due to cervical insufficiency related to genetic 
cervical weakness or trauma (Anum et al., 2009). However, there is no proven method 
to identify cervical insufficiency from cervical shortening due to other causes, and the 
exact involvement in preterm birth is not known.  
 
1.2.1.7 Intrauterine infection 
Intrauterine infection is a significant contributor to preterm birth and involves 
activation of the innate immune system (Keelan, 2018). Toll-like receptors (TLRs) are 
cell-surface proteins responsible for recognition of patterns of microorganisms (Akira 
et al., 2006). TLRs initiate the inflammatory cascade by the release of various 
inflammatory mediators including cytokines and chemokines (Mogensen, 2009). The 
release of these proinflammatory mediators results in production of prostaglandins that 
ultimately promote uterine contractility (Institute of Medicine Committee on 
Understanding Premature and Assuring Healthy, 2007).  
Even though these risk factors are well recognised, a significant proportion of 
sPTB occurs without any apparent cause. Whilst preterm birth is seemingly multi-
factorial, many of these risk factors appear to share aetiological mechanisms. A better 
understanding of these aetiological factors that operate through multiple 
pathophysiologic pathways may improve our ability to prevent spontaneous preterm 
birth.  
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Figure 1.6: Proportion of women delivering preterm at various gestational age cut-
offs according to the mid-trimester cervical length indicating that cervical length is the 
strongest predictor of preterm birth (Glover and Manuck, 2018). 
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1.2.2 Preterm birth: an inflammatory disorder 
Conventionally, whether labour and delivery have occurred at term or preterm, they 
have been regarded to be driven by the same underlying pathophysiology, a process 
marked by production of a range of inflammatory mediators (Institute of Medicine 
Committee on Understanding Premature and Assuring Healthy, 2007). Labour is 
characterised by uterine contractility, rupture of fetal membranes and cervical 
remodelling (Timmons et al., 2010). This process is regulated by an increased 
circulation of cytokines and leukocyte activation that facilitates the transition from an 
inactive to a pro-inflammatory environment (Yuan et al., 2009). In normal term 
pregnancies, there is a withdrawal of active suppression of the decidua inducing 
inflammation accompanied by the release of various biologically active mediators 
inducing labour (Norwitz et al., 2015). Preterm birth can occur if there is dysregulation 
of this process earlier in gestation or if other exogenous factors activate the 
inflammatory cascade. This may occur, for example, if there is placental abruption or 
infection.  
 
1.2.2.1 Infection and Inflammation  
Infection is a significant contributor to preterm birth (Klein and Gibbs, 2005). The 
mechanism by which an infectious insult activates the immune system to cause 
inflammation remains unknown but likely involves innate immune pattern recognition 
receptors and their regulators. An intrauterine infection can be restricted to the decidua, 
spread to the amniotic sac and eventually to the fetus (DiGiulio et al., 2010) (Figure 
1.7). As described above, microorganisms are recognised by the cells of the maternal-
fetal interface through TLRs and nod-like receptors and activate the immuno-
inflammatory cascade. These cascades may be activated by mechanisms that are not 
primarily caused by an infectious insult but are associated with an inflammatory 
response.  
Although the amniotic cavity is thought to be largely sterile, accumulating 
evidence suggests that intra-amniotic infection can be caused by genital Mycoplasmas 
(Kim et al., 2015a). Microorganisms invade the amniotic cavity by various 
mechanisms (Goncalves et al., 2002, Goldenberg et al., 2008, Goldenberg et al., 
2000b). These are by way of ascending infection, where organisms from the vagina 
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penetrate the cervix / cervical mucus barrier, blood borne infection – penetrating the 
placenta, iatrogenic infection – through an invasive procedure (e.g. amniocentesis) or 
spread of an intra-abdominal / peritoneal infection entering the uterus through the 
fallopian tubes. Most infections are attributed to the ascending (vaginal / cervical) path 
(Romero et al., 2014); although there is a consensus that ascent occurs during 
pregnancy (Koren et al., 2012), the precise timing is unknown. Infection likely 
precedes the onset of spontaneous labour and may therefore be detectable at an early 
stage of pregnancy.  
 
1.2.2.2 Chorioamnionitis  
Chorioamnionitis is responsible for 40% of all preterm births worldwide (Lamont, 
2003). This rate is even higher in extreme sPTB as suggested by a study that reported 
a positive test for an infectious insult in 79% of patients who laboured spontaneously 
<28 weeks (Onderdonk et al., 2008, Watts et al., 1992). Chorioamnionitis involves 
inflammation of the amnion and chorion and is primarily caused by bacterial infection 
(Leviton et al., 1999, Hagberg et al., 2002). Multiple types of vaginal bacteria such as 
Ureaplasma urealyticum, Gardnerella vaginalis, Chlamydia trachomatis, Neisseria 
gonorrhoea, Mycoplasma hominis, Group B Streptococcus, and Trichomonas 
vaginalis are associated with inducing preterm labour (Nelson et al., 2009, Martius et 
al., 1988, Hillier et al., 1995).  
The inflammatory process is generally observed as a continuum. The initial 
stages of the inflammatory response involve neutrophils of maternal origin migrating 
from the decidual vessels while the later stages involve neutrophils from fetal origin 
migrating from the umbilical cord (Kim et al., 2015a).  Placental inflammation can be 
broadly classified as: (1) the maternal inflammatory response (MIR), inflammation 
infiltrating into the chorion, amnion or decidua (Redline et al., 2003); and (2) the fetal 
inflammatory response (FIR), inflammation extending to the chorionic plate, umbilical 
cord, and fetal vessels (Gomez et al., 1998). Both types of inflammation are associated 
with preterm birth and several neonatal complications including cerebral palsy, lung 
disorders, necrotizing enterocolitis, and intraventricular haemorrhage (Strunk et al., 
2014, Claud, 2009, Ballabh, 2010).  
Systemic involvement including hematologic abnormalities are found to be 
linked to fetuses that have a FIR (Romero et al., 2011). Histologic chorioamnionitis 
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(HCA) is linked with microbial invasion in the amniotic cavity and is considered as an 
indicator of maternal inflammation of the placenta, whereas funisitis, or inflammation 
of the umbilical cord, is a marker of fetal inflammation. Reports have suggested that 
33% of neonates born prematurely have HCA (Menon et al., 2010, Thomas and Speer, 
2011, Kim et al., 2015b, Bersani et al., 2012).  
Clinically, intrauterine infection is diagnosed by examining the amniotic fluid 
and/or the placenta (Tita and Andrews, 2010). This presents a problem as this 
diagnosis is most easily made after delivery (allowing examination of the placenta) or 
requires an invasive test (amniocentesis) that carries its own risks to mother and fetus. 
If amniotic fluid is available, then this can be used to measure leuko-attractants, 
glucose concentration, white blood cell count and interleukin-6 (IL-6) and perform a 
gram-stain. Combinations of these tests have high sensitivity and specificity in 
identifying pregnancies that are infected (Romero et al., 1993, Gomez et al., 1994). In 
most clinical units, an amniocentesis in not routinely performed for all women 
attending with threatened preterm labour – in addition to the risks of invasive testing, 
this requires a skill set that is not readily available on most labour wards.  
Histologic examination of the placenta, that allows accurate diagnosis of HCA, 
is regarded as the gold standard method for identifying infection – but is only possible 
post-delivery and cannot, therefore, be used to guide obstetric management. In recent 
years, several research groups have made attempts to develop non-invasive and rapid 
prenatal tests for diagnosing intrauterine inflammation by examining maternal blood. 
These tests include measuring maternal levels of CRP and other interleukins (ILs) to 
diagnose HCA (Le Ray et al., 2015, Samejima and Takechi, 2017, Oh et al., 2011). 
CRP is an acute phase reactant synthesized by the liver in response to inflammatory 
stimuli (Pepys and Baltz, 1983). CRP is essentially used when an obstetrician needs to 
monitor various inflammatory disorders including chorioamnionitis (Aggarwal and 
Pahwa, 2018). Several groups have confirmed increased CRP levels in maternal serum 
and plasma to be associated with HCA (Hvilsom et al., 2002, Pitiphat et al., 2005, 
Vogel et al., 2005). However, due to its low sensitivity, its application in a diagnostic 
setting is questionable (Stepan et al., 2016, Amirabi et al., 2012, Smith et al., 2012). 
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1.2.2.3 Vaginal microbiome 
Several studies have found that preterm birth is associated with bacterial vaginosis 
(Manns-James, 2011, Subtil et al., 2002). Lactobacillus species dominate the vaginal 
microbiome in non-pregnant women (Nasioudis et al., 2017). Low abundance of 
lactobacilli and consistent presence of anaerobic bacteria (Gardnerella vaginalis, 
Mycoplasma hominis, Parvimonas micra, Aerococcus christensenii) are associated 
with preterm delivery (Stafford et al., 2017, Donders et al., 2009). While there is a 
significant body of literature describing a local inflammatory response in women with 
vaginitis due to trichomonas and candida, the same cannot be said for bacterial 
vaginosis despite the presence of extensive microbial growth (Rasti et al., 2014, Hosny 
et al., 2017). A recent study carried out DNA sequencing of the vaginal microbiome 
in an African-American women cohort (Stout et al., 2017). The researchers 
demonstrated that there was a decrease in the amounts and diversity of microbes in 
women who delivered preterm compared to those who delivered at term. The decrease 
was observed earlier in gestation suggesting that this period is crucial for determining 
subsequent term and preterm events.  
Although there is convincing evidence of a causal association between 
intrauterine infection and sPTB, the impact of antibiotics for prevention of preterm 
birth has been disappointing (Nygren et al., 2008, Guise et al., 2001, Kekki et al., 
2001b, Carey et al., 2000). There are several possible explanations for this, one is that 
preterm birth is a syndrome that involves multiple aetiological pathways and infection 
represents only one potential cause. Another is that clinical trials have not focused on 
antibiotics appropriate for the specific microbial population or the antibiotics have not 
been administered at an appropriate time to treat the infection.  
 
1.2.2.4 Placental microbiome 
In recent years, research has shown that the placenta, originally thought to be a sterile 
organ, harbors its own microbiome (Nuriel-Ohayon et al., 2016). Sequencing studies 
suggest temporal alterations during pregnancy are accompanied by remodelling of this 
microbiome (DiGiulio et al., 2015). However, the precise mechanisms by which 
microbes inhabit the placenta and cause the remodelling are far from understood. 
Aagaard et al. suggest that there are differences in the abundance of microbes such as 
Burkholderia, Actinomycetales, Alphaproteobacteria, Paenibacilli and Escherichia 
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coli in placentas obtained from term and preterm women (Aagaard et al., 2014). It is 
not, however, completely clear whether the alterations in microbial patterns are purely 
characteristic of gestational age or indicative of different pathophysiological stages of 
placental and/or fetal development. 
Interestingly, a study has documented increased expression of human 
leukocyte antigen (HLA) in preterm placenta compared to term placenta (Stout et al., 
2015). The findings of this study suggest that maternal factors contribute to the 
aetiology of preterm birth as these HLAs are involved in maternal tolerance of the 
fetus and regulation of maternal immune system. However, the mechanism by which 
levels of HLA influence the placental microbiome remains unknown. 
To summarize, all pregnant women carry multiple species of bacteria within 
their genital tract. The interaction between their microbiota and / or with other infective 
pathogens can lead to an inflammatory response and this appears to play a central role 
in determining the timing of labour. The process may be further complicated by 
changes in maternal immunity that either have a genetic base or may be induced by 
pregnancy. Whilst most of the work attempting to define the presence of a FIR has 
been performed in patients who are symptomatic for preterm birth, there is potential 
to define changes associated with this pathway at an earlier stage of pregnancy. 
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Figure 1.7: Routes of infection associated with preterm birth. Microorganisms can 
gain access to the amniotic cavity by: A) ascending from the vagina and the cervix; 
(B) haematogenous dissemination through the placenta; (C) accidental introduction at 
the time of invasive procedures; and (D) by retrograde spread through the fallopian 
tube (Goldenberg et al., 2008). 
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1.2.3 Circulating factors in preterm birth in various biological systems 
Several infection-related markers including cytokines have been linked to preterm 
birth. A variety of bio-specimens including maternal and fetal blood, amniotic fluid, 
urine, cervicovaginal secretions, and placental tissue have been used to examine the 
role of cytokines in preterm birth. Cytokines mediate inflammation and exhibit 
autocrine, paracrine and endocrine functions (Zhang and An, 2007). They are involved 
in complex networks involved in establishment and maintenance of pregnancy 
(Mathialagan and Roberts, 1994).  
There is overwhelming evidence confirming correlations between increased 
levels of circulating pro-inflammatory cytokines and preterm birth (El-Shazly et al., 
2004, Fortunato et al., 2002a, Gucer et al., 2001, Nadeau-Vallee et al., 2016, Ruiz et 
al., 2012). The release of pro-inflammatory cytokines is followed by leucocytosis 
which results in apoptosis, premature rupture of membranes along with cervical 
remodelling and onset of premature labour. Several publications have appeared in 
recent years implicating Interleukin-1 (IL-1), tumor necrosis factor (TNF), and IL-6 in 
the onset of preterm birth (Gervasi et al., 2012). Furthermore, polymorphisms in pro- 
and anti-inflammatory genes have been associated with preterm birth (Romero et al., 
2007, Keelan, 2011). 
The inflammation cascade initiating preterm birth is mediated by several pro-
inflammatory factors. Interleukin-1β (IL-1β), a major player in the inflammation 
process, promotes prostaglandin production when bound to TNF-α (Nadeau-Vallee et 
al., 2016). There is a vast body of evidence implicating TNF-α in preterm birth 
associated with infection (Fortunato et al., 2002b, Liang et al., 2010, Chen et al., 2003). 
TNF-α is produced by human decidua in response to microbial colonization (Casey et 
al., 1989). Furthermore, elevated levels of TNF-α have been reported in the amniotic 
fluid of women affected by intrauterine infection (Puchner et al., 2012). It has also 
been reported that there is an increased risk of preterm birth in patients with an 
abnormal vaginal flora who are genetically predisposed to produce an excess of TNF-
α (Srinivasan et al., 2009). IL-6 and IL-8 are another two factors that are involved in 
the inflammation process associated with preterm birth (Wu et al., 2013, Romero et 
al., 1990, Velez et al., 2008a, Lee et al., 2015). IL-6 is linked to prostaglandin synthesis 
via the production of acute phase proteins that accompany inflammatory disease while 
IL-8 plays a vital role in cervical ripening (Young et al., 2002).  
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Whilst most ILs promote inflammation, others, such as Interleukin-10 (IL-10) 
help control the inflammatory response and limit associated tissue damage (Couper et 
al., 2008). IL-10 is highly expressed in the uterus and placenta during pregnancy and 
a reduction in expression has been implicated in pregnancy complications linked to 
inflammation (Thaxton and Sharma, 2010). IL-10 is thought to inhibit IL-1 synthesis, 
by which it keeps the immune response in check (Mobini et al., 2016). Transforming 
Growth Factor β (TGF – β) is another anti-inflammatory factor which assists in 
regulating progesterone, a vital hormone to maintain pregnancy (Ni and Li, 2017).  
Maintaining an equilibrium of pro-inflammatory and anti-inflammatory 
cytokines is critical for implantation, development of the fetus and maintenance of 
pregnancy (Liang et al., 2015). The inflammatory response normally builds up over a 
period of time, reaching a point at which it triggers parturition. It may be possible to 
recognise this process weeks or months prior to the onset of labour – providing an 
opportunity to intervene and change the outcome of the pregnancy. 
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1.3 Current screening strategies 
Clinically, women fall into one of three categories when screening for preterm birth. 
Some women are defined as being high-risk at the time of presentation, this is typically 
the case if they have a history of previous preterm birth, are known to have a short 
cervix (due to an operative procedure) or have a multiple gestation. Other women, who 
are also asymptomatic at the time of initial presentation, would be considered low-risk 
(generally women with singleton pregnancies without a history of a previous preterm 
birth or of a risk factor for cervical incompetence). The final group are women who 
are symptomatic for preterm birth. These women, who attend with abdominal pain and 
or vaginal bleeding are typically seen at a slightly later point in pregnancy. The first 
two categories allow screening with a view to prediction of an event that will occur 
sometime in the future. In contrast, symptomatic women are screened to determine 
whether they are at immediate risk of developing spontaneous preterm labour. 
 
1.3.1 Screening women who are high risk but asymptomatic for preterm birth 
As discussed previously (Section 1.2.1), several risk factors for preterm birth are 
recognised and at the time of the first clinical visit in pregnancy, maternal 
characteristics and previous obstetric history can be used to define women as high or 
low risk for preterm birth. The strongest historical risk factor for subsequent preterm 
birth is a previous preterm birth – and the risk is highest for women who laboured the 
earliest in gestation (Carr-Hill and Hall, 1985, Ekwo et al., 1993, Mercer et al., 1999, 
Ekwo and Moawad, 1998, Adams et al., 2000). Other women who are recognised as 
high risk for preterm birth are those that have had previous cervical surgery (large loop 
excision of the transformation zone or cone biopsy) and these women are also typically 
considered to be high risk (Chandiramani et al., 2011, Poon et al., 2012).  
Use of this binary form of risk assessment (in which women either have these 
risks factors or they do not) is not a very sensitive screening tool; for instance, 50% of 
the population will not have a prior pregnancy history. This screening strategy is 
however typically used to inform models of care – and women at risk of preterm birth 
will often be placed in a high-risk, medicalised model. The accuracy of this historical 
form of assessment could be checked using a number of investigative tools which have 
higher screening efficacy – and which can be applied to this high-risk population. The 
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findings of these investigations may then be used to define the most appropriate 
management pathway. 
If a woman is deemed high risk, then it is possible to immediately assess the 
length of the cervix with ultrasound. Cervical length is known to be a good predictor 
of risk of preterm delivery. If a woman who has a high-risk - on the basis of previous 
preterm delivery – has a short cervix (< 25mm) – then this will increase the risk of 
subsequent preterm delivery even further – and will often lead the clinician to instigate 
some preventative treatment – such as provision of vaginal progesterone therapy or 
cervical cerclage (Romero et al., 2018, Althuisius et al., 2000, Alfirevic et al., 2017). 
Fetal fibronectin (fFN) is another valuable tool to define the risk of sPTB in a 
high-risk asymptomatic group (Lockwood et al., 1991). fFN is an adhesive protein, 
found at the maternal–fetal interface and acts like a glue between the amniotic fluid 
and the inner lining of the uterus. The release of this glycoprotein in the vaginal 
discharge is an indicator of inflammation caused by placental/membrane damage 
(Zhang et al., 2014). Typically, in a normal pregnancy fFN is very low (<50 ng/mL) 
in cervico-vaginal secretions (Lockwood et al., 1991). Levels of fFN are found to be 
elevated before 22 weeks and after 35 weeks’ gestation (Kiefer and Vintzileos, 2008). 
A concentration of ≥50 ng/mL at ≥22 weeks’ gestation is associated with a greater risk 
of sPTB (Levine et al., 2018). Interestingly, fFN has been found to be most informative 
when the result is negative. Subsequently, several systematic reviews and meta-
analyses have indicated a negative fFN to identify women who are unlikely to deliver 
within seven to ten days, and do not require intervention in the form of antenatal 
corticosteroids or tocolytic agents (Revah et al., 1998, Honest et al., 2002).  
In reality, only 5% of pregnant women will have had a prior preterm birth and 
a surveillance program that is based purely on identifying this high-risk cohort will not 
detect >60% of preterm births that are actually seen in a ‘low risk’ cohort (Greco et 
al., 2012). The only way that these cases can be successfully identified is to change 
the screening strategy so that all women are offered assessment using either ultrasound 
(cervical length assessment) or fFN testing – so that the high-risk group can be 
determined using this assessment tool rather than history alone. 
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1.3.2 Screening low risk women who are asymptomatic of preterm birth 
95% of women who have their first clinic visit during pregnancy are low-risk 
for preterm birth based on their previous obstetric history. Several studies have shown 
that cervical length is a predictive tool for preterm birth in low-risk as well as high-
risk patients (Iams et al., 1996, Taipale and Hiilesmaa, 1998, Heath et al., 1998). 
Furthermore, there is good evidence that risk of preterm birth can be reduced by 
treating these women with progesterone (Romero et al., 2012). fFN is not routinely 
used to screen low-risk asymptomatic women due to lack of evidence for improved 
perinatal outcomes.  
There is evidence of an elevated risk of spontaneous preterm delivery in 
women that have a short cervix (<25mm) (Iams et al., 1996), and this is supported by 
the fact that sonographic measurement of cervical length at 23 weeks is highly 
reproducible (Heath et al., 1998); a mean cervical length of 38 mm was reported, that 
was comparable to other studies that assessed low-risk populations by measuring 
cervical length at 20-24 weeks. A number of other groups have made similar 
observations and these data were collated in a meta-analysis that reported transvaginal 
cervical sonography as an effective tool to identify women at an increased risk of sPTB 
(Honest et al., 2002). 
Good normative ranges for cervical length have been established across 
gestational age (Salomon et al., 2009). If assessment is made at 18 - 23 weeks, the 
shorter the cervix is, the more likely it will be associated with early delivery (Celik et 
al., 2008). Rather than using these likelihood ratios to give individualised risks of 
preterm birth, most groups consider a fixed cut-off (25 mm) to be associated with an 
increased risk of preterm birth. Screening using this cut-off will identify ~3% of 
women to be at risk and this cohort will include 80% of women that deliver 
spontaneously before 34 weeks (Salomon et al., 2009, Celik et al., 2008). 
Women that have a short cervix can be offered progesterone, cerclage or a 
cervical pessary (Alfirevic et al., 2013). A meta-analysis reporting the impact of 
progesterone showed a 45% reduction in rates of sPTB in women that were identified 
as being at risk and given treatment (Hassan et al., 2011). The data to support use of a 
suture or pessary in this situation appears to be slightly weaker. According to a meta-
analysis that included three studies, the application of cervical pessary has not proven 
to be effective in lowering the risk of sPTB (risk ratio, 0.71; 95% confidence interval, 
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0.21-2.43; p = 0.59) (Conde-Agudelo et al., 2013). Furthermore, there is no evidence 
that identifies whether a combination of these treatments is more useful than one 
intervention alone.  
Cervical assessment is traditionally performed at 18-23 weeks and there will, 
therefore, be a small cohort of pregnancies that are identified too late to prevent 
spontaneous preterm labour occurring. There is no data currently available in the 
literature that proves cervical length to be effective in improving outcomes in 
asymptomatic women who are screened after 24 weeks’ gestation. If it were possible 
to identify women earlier, then preventative strategies may be more effective. The 
development of a simple blood test for screening would also negate the need for 
transvaginal cervical assessment in all pregnancies – a procedure that requires 
expensive ultrasound equipment, trained staff, image interpretation, and is 
inconvenient for women. 
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1.3.3 Screening women symptomatic of preterm birth 
This cohort is different as women typically attend with symptoms of preterm birth later 
in pregnancy rather than at the time of their antenatal booking appointment or their 20-
week scan. The purpose of screening to define a high-risk cohort is also different: If 
women are defined as being at high-risk in early pregnancy then it is possible to 
provide a prophylactic intervention that will prevent progression and clinical 
development of the disorder.  If women are identified after they have become 
symptomatic, then the focus of care is on ensuring they are in an appropriate 
environment of delivery, have appropriate neonatal support available and are given 
drugs (steroids and magnesium sulphate) that will reduce mortality and morbidity for 
the infant. 
Cervical examination through routine ultrasound is not associated with a 
significant reduction of sPTB (Iams et al., 1996, Heath et al., 1998, Honest et al., 
2003). Digital cervical evaluation using the Bishop Score is an effective parameter for 
the prediction of preterm birth (Newman et al., 2008). A high Bishop score is 
predictive of greater risk of preterm birth. It is not possible to recommend the use of a 
tool more than another (e.g. cervix ultrasound versus vaginal examination) in women 
experiencing preterm labour.  
Screening for fFN in the genital tract of patients with preterm labour has an 
excellent negative predictive value for sPTB at 48 hours and 7 days (Goldenberg et 
al., 1996, Honest et al., 2002, Peaceman et al., 1997). Nevertheless, its use in 
symptomatic women is not associated with a reduction of preterm birth rate and is 
therefore not recommended. However, the rationale for screening women with 
symptoms of preterm labour is different from that of primary prediction and prevention 
and is not the focus of the current work. 
 
1.3.4 Current predictive tests for spontaneous preterm birth  
1.3.4.1 Ultrasonographic assessment of cervical length  
Typically, risk assessments for predicting preterm birth include examining the cervix, 
maternal demographics, obstetric history and biochemical tests (Table 1.1). Currently, 
a short cervical length in mid-trimester, irrespective of prior pregnancy history is one 
of the strongest indicators of spontaneous preterm birth. As noted in the above 
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sections, previous studies have documented that the risk of sPTB is inversely 
proportional to cervical length. Transvaginal ultrasound measurement is regarded as 
the ‘gold standard’ for cervical length as it is a reliable, safe and highly reproducible 
method when performed by trained providers (McIntosh et al., 2016). A threshold 
range of 20 to 30 mm is regarded as “short” for cervical length depending on the 
gestational age and the study population (Lim et al., 2011). Various studies across 
different populations show similar results. Typically, a cervical length less than 30 mm 
is regarded as “short” in the mid-trimester, as this corresponds to the 10th percentile 
for this gestational age (Hibbard et al., 2000). Additionally, there is a higher risk of 
sPTB if the cervix is found to be short at 18 weeks’ gestation compared to 22 weeks 
(Owen et al., 2004).  
 
1.3.4.2 Fetal fibronectin 
The quantitative fFN (QfFN) assay, on the other hand, is in use in several countries for 
screening women to predict sPTB. Many studies have confirmed improved clinical 
performance for sPTB screening when fFN is combined with other risk factors such as 
cervical length (Hincz et al., 2002, Gomez et al., 2005, Schmitz et al., 2006, Ness et 
al., 2007). Nonetheless, additional research is still required to determine the accuracy 
of the QfFN assay, in combination with other screening modalities, in optimising 
neonatal outcomes for women at risk of sPTB, regardless of previous history of 
preterm birth. 
 
Table 1.1: An overview of risk assessment approaches for preterm birth. Adapted from 
Haque et al., 2016. 
Risk scoring  Physical examination Biochemical tests 
Medical history Cervical length  Pregnancy Associated Placental 
Protein (PAPP-A), serum Alpha-
fetoprotein 
Demographic 
factors 
Fetal crown rump 
length 
Placental protein 13 
Psychological and 
lifestyle factors  
Uterine artery 
pulsatility index 
Cervicovaginal IL-6/8, phIGFBP1, 
fFN 
  46 
1.3.5 Current preventive measures / intervention strategies for spontaneous 
preterm birth  
In the last few years there has been growing interest in treating low risk women with 
a short cervix in mid-trimester with progesterone or cervical cerclage. Progesterone is 
the most widely studied medications for prevention of preterm birth in women with a 
prior history of preterm birth. Several randomized clinical trials have documented a 
significant decrease in the rate of sPTB in women with a prior history of preterm birth 
who received vaginal progesterone commencing in the mid-trimester to 37 weeks’ 
gestation (Karbasian et al., 2016, El-refaie et al., 2016). These findings have further 
been confirmed in systematic reviews and a meta-analysis of asymptomatic women 
with a short cervix and multiple gestation in the mid‐trimester (Romero et al., 2018). 
Moreover, administration of vaginal progesterone has proven to be effective in 
decreasing the risk of sPTB even in those women without a prior history of preterm 
birth who are incidentally found to have a short cervix (Norwitz and Caughey, 2011). 
Progesterone has anti-inflammatory properties and thus an important role in 
maintaining pregnancy by decreasing the production of prostaglandins and 
subsequently limiting uterine contractility and cervical dilation and effacement; 
however, its exact mechanism of action in preventing sPTB is not known (Siiteri et al., 
1977). 
Cervical cerclage is a well know surgical technique employed to prevent 
recurrent sPTB in women known to have cervical insufficiency (Wang et al., 2016). 
The cervix acts as a physical barrier and protects the uterus and growing fetus from 
bacterial infections ascending from the vaginal canal (Myers et al., 2015). A cerclage 
is thought to be beneficial in high-risk women as it provides structural support to the 
cervix (Nott et al., 2016). Nevertheless, some women fail treatment and still deliver a 
very preterm infant. In current clinical practice, women with a prior sPTB <34 weeks 
may be offered the option of prophylactic cerclage - normally performed after the 11-
13-week scan has demonstrated normal fetal anatomy - or cervical length screening 
with serial transvaginal scans through the second trimester. If serial transvaginal 
ultrasound assessments indicate shortening of the cervix without symptoms of preterm 
labour, cerclage placement may be considered.  
Prescription of vaginal progesterone or cervical cerclage have been reported to 
be equally effective in preventing preterm birth in women with a history of previous 
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preterm birth and a short cervix at 16-20 weeks (Conde-Agudelo et al., 2018). In the 
absence of clear benefit of cerclage over vaginal progesterone in otherwise low risk 
women with a short cervix, progesterone is generally the preferred treatment due to 
the lower risk of surgical complications.   
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1.4 Identification of specific proteins associated with preterm birth using -Omics 
approaches 
Currently, there is a substantial gap in the knowledge base concerning molecular 
mechanisms underlying spontaneous preterm birth. Exploring and defining the 
proteome (i.e. the entire set of proteins expressed in an organism, cell or tissue 
including all isoforms and posttranslational modifications (PTMs)) of the first 
trimester maternal serum in women who have delivered preterm spontaneously should 
allow improved insight into the evolution and progression of this devastating condition 
(Wilkins et al., 1996, Blakeley et al., 2010). Proteomics is thus likely to provide new 
targets for more effective medical management and potentially a novel method of 
minimally-invasively providing a prognosis and/or tracking paradigm for women 
suffering from this complex and debilitating condition. One of the primary goals of 
clinical functional proteomics is to characterise the cross-talk within biological 
samples, such as serum, through the various molecular pathways and interactions (e.g. 
cell signalling, apoptosis, angiogenesis, cellular proliferation, oxidative stress, etc.) in 
healthy and diseased states (Wu et al., 2014). 
Notably, PTMs have been recognised to play crucial roles in signalling 
mechanisms as they regulate the activity, localization and interaction of proteins with 
one another and with other molecules (Beltrao et al., 2013). Identifying consistent 
changes in the proteome, and specific PTMs to proteins (e.g. phosphorylation and 
glycosylation) is likely to provide avenues for early intervention and prediction of 
sPTB at an earlier stage of pregnancy. This should improve research outcomes with 
progressively wider realization that proteomes are composed of proteoforms. 
 
1.4.1 Post translational modifications  
Alterations to proteoforms may indicate different biological activities (Godovac-
Zimmermann et al., 2005). These proteoforms may include PTMs by phosphorylation, 
acetylation, methylation, or glycosylation (Duan and Walther, 2015). Protein PTMs 
contribute to the complexity that arises from the genome to the proteome level.  
Depending on the nature and type, PTMs can be reversible/irreversible and can 
occur at any stage in the "life cycle" of a protein (Boyer, 2006). For instance, some 
proteins are modified shortly after the process of translation to either facilitate protein 
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folding, maintain protein integrity or to help the protein traverse to the nucleus or 
membrane (Jenkins et al., 2008). Other proteins are modified after the completion of 
folding to stimulate catalytic/biological activity of the protein. (Boyer, 2006).  
Although only 5% of the proteome comprises enzymes, more than 200 types 
of PTMs are due to specific enzymatic activities (Duan and Walther, 2015). These 
enzymes modify proteins by catalysing the addition or removal of functional groups 
therefore altering protein activity and biological function. For example, kinases that 
add phosphate groups to proteins and proteases which cleave peptide bonds and 
therefore remove a specific sequence from a protein (Knorre et al., 2009).  
The investigation of proteoforms is particularly significant in understanding 
the molecular basis of preterm birth. Identification of consistent changes in specific 
PTMs (e.g. phosphorylation, glycosylation) defining select proteoforms is likely to 
provide better understanding of protein-protein interactions, signalling pathways, and 
ultimately provide opportunities for intervention and prediction of preterm birth at an 
earlier stage of pregnancy. My focus in the current research, is on PTM such as 
phosphorylation and glycosylation and their potential role in defining early biomarkers 
predictive of preterm birth. 
 
1.4.1.1 Role of protein phosphorylation in preterm birth 
Phosphorylation plays fundamental roles in the regulation of cell function, apoptosis 
and signalling cascades (Ardito et al., 2017). In recent years, research on role of protein 
phosphorylation in the pathogenesis of various disease states has gained attention 
(Harsha and Pandey, 2010, Hanahan and Weinberg, 2011, Javidi-Sharifi et al., 2015, 
Zhu et al., 2015). One rapid test involves the detection of a post-translationally 
modified species of insulin-like growth factor binding protein-1 (IGFBP-1) in cervical 
secretions in women who are already symptomatic for preterm birth (i.e. in 2nd 
trimester) (Kekki et al., 2001a). The phosphorylated species of this protein i.e. 
phIGFBP-1 is mainly synthesized in the decidual tissues during pregnancy (Akercan 
et al., 2004, Lembet et al., 2002). The presence of phIGFBP-1 in cervical secretions 
may be an indicator of tissue damage at the choriodecidual interface. The fetal 
membrane begins to separate from the decidua in the earlier stages of labour. At this 
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stage, the presence of phIGFBP-1 in cervicovaginal secretions has been suggested as 
a predictor of preterm delivery but no testing has been done during the first trimester 
of pregnancy.  
 
1.4.1.2 Role of protein glycosylation in preterm birth 
Glycosylation is recognised as one of the most common and major PTMs responsible 
for regulation of anti-inflammatory immune responses (Caramelo and Parodi, 2007, 
Helenius and Aebi, 2004, Lowe and Marth, 2003). Glycosylation describes the process 
whereby sugar-moieties attach to the primary protein. A diverse group of sugar 
complexes and protein species may be involved; ranging from simple monosaccharide 
to highly complex polysaccharide modifications (Stowell et al., 2015). Abnormal 
glycosylation states have been associated with pathological conditions related to 
human implantation (Clark, 2015). Previous studies indicate alterations in 
glycosylated serum proteins such as IgG and α1-antitrypsin during pregnancy (Bondt 
et al., 2013, Ruhaak et al., 2014). Increased levels of pregnancy associated anti-
inflammatory IgG Fc-linked N-glycan galactosylation and sialylation has also been 
demonstrated by several groups (Bondt et al., 2013, Raju and Lang, 2014, van de Geijn 
et al., 2009).  
Due to a high amount of glycoconjugates in the human uterus, not only the 
sperm, the implanting fetus and embryo can bind effectively, but also any pathogen 
that may gain entry to the uterus (Jones and Aplin, 2009, Carson, 2002). During the 
luteal phase of the menstrual cycle, secretions of the endometrial glands increase 
markedly (Jones et al., 2001). These secretions are supplemented with nutrients and 
growth factors that maintain the implantation of the embryo and the subsequent 
development of a viable fetus (Clark, 2015). It is still unknown whether there is a link 
between defective placental or uterine glycosylation and adverse obstetric outcomes 
including preeclampsia, intrauterine growth restriction and preterm birth. Furthermore, 
the role of glycans linked to uterine and trophoblast glycoconjugates also remains 
unknown. 
Recent studies, however, have reported the presence of altered glycosylation 
in trophoblasts obtained from patients that develop preeclampsia and preterm birth 
(Marini et al., 2011). Alterations in the pattern of β1 integrin glycosylation in placentas 
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obtained from women that had early spontaneous miscarriage relative to matched 
controls have also been identified (Zhang et al., 2015). The functional significance of 
shifts in glycosylation and its potential role in the development of preterm birth is yet 
not well-defined. 
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1.4.2 Omic approaches 
Until now, most of the research focussed in the field of molecular biology is related to 
DNA (genomics) analysis and thus on the message (i.e. mRNA or transcriptomics) 
rather than the translation product of this message (i.e. the protein or proteomics). The 
rapidly expanding knowledge relating to altered cellular molecular processes in 
diseased states has brought about a “systems biology” approach and combined the use 
of the various complementary “-omics” (e.g. genomics, transcriptomics, proteomics, 
metabolomics, lipidomics) methods.  
To date, most of the research focused on understanding the pathophysiology of 
preterm birth has involved the assessment of potential genetic markers. However, 
application of these as clinical markers, targets for drug intervention, or for the 
development of therapeutic agents is likely to be limited. Genomic data will provide a 
basis on which protein studies may be built. However, genomics alone will not provide 
the functional and biochemical information on messenger or protein abundance or 
speciation as the genome is relatively static when compared to the proteome that 
evolves in response to myriad intra- and extracellular environmental signals (Graves 
and Haystead, 2002). 
Transcriptomic analyses, on the other hand, focus on identifying critical 
mRNAs as they are directly coded by the genome (Han et al., 2015). Proteomic 
investigation offers molecular and cellular information relating to protein abundance 
and the diversity of proteoforms present (Larochelle, 2016). Identifying changes in 
copy numbers or altered levels of DNA or RNA respectively does not necessarily 
identify changes at the protein level and therefore might not be directly relevant to the 
biological nature of a physiological state. In contrast, systems biology approaches, 
including proteomics and lipidomics provide direct information concerning a given 
state, and thus opportunities for study of both healthy and adverse pregnancy outcomes 
such as preterm birth. 
Omics strategies offer much in terms of biomarker discovery, as multiple 
molecules can be assessed simultaneously. There has been an increasing trend in the 
use of omics approaches in reproductive medicine. In the last decade, omics 
(genomics, transcriptomics or proteomics) research related to preterm birth has 
attracted much attention. (McPherson and Manuck, 2016, Sheikh et al., 2016, Paquette 
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et al., 2018, Bukowski et al., 2017, Law et al., 2015, Bradford et al., 2017, Horgan and 
Kenny, 2011). However, most of this research has focussed on single omics 
approaches and have failed to be translated into clinical practice mainly due to lack of 
reproducibility. 
 
1.4.3 Proteomics 
As defined above, the proteome comprises of all protein species including splice 
variants and PTMs present in an organism at a given point in time and proteomics 
refers to the large scale study of protein species and the applications of technologies 
for their identification and quantification (Aslam et al., 2017, Aebersold and Mann, 
2016). Understanding the proteome is crucial for biomarker discovery because protein 
species are most likely to be impacted by the disease or disease response (Kavallaris 
and Marshall, 2005). 
The impact of proteomic research within the last decade in attempting to 
understand the molecular biology of reproductive medicine and gynaecological 
diseases has been enormous (Kolialexi et al., 2008, Kosteria et al., 2017, De Rose et 
al., 2018, Hernández-Núñez and Valdés-Yong, 2015, Butt et al., 2006). Specifically, 
in preterm birth, the application of proteomics has not only attempted to define the 
aetiology, great emphasis has also been placed on the search for discriminatory 
biomarkers during the early phases of pregnancy (Kacerovsky et al., 2014, Law et al., 
2015, Buhimschi et al., 2008, Bujold et al., 2008, Bradford et al., 2017). 
However, there continues to be a substantial gap in the knowledgebase 
concerning molecular mechanisms underlying preterm birth. Exploring, defining and 
understanding the maternal serum proteome should allow improved insight into the 
evolution and progression of this disease in women from various ethnic backgrounds. 
Proteomics may also provide new targets for more effective medical management and 
potentially a novel method for rapid, cost-effective prognosis and/or diagnostic 
tracking of women suffering from this condition (Figure 1.8).  
The following sections will describe the predominant techniques for 
comparative proteomics employed in the current research and the bioinformatics 
methods used to extract significant quantitative information from these techniques. 
  54 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: The role of proteins and post translational modification in understanding 
disease. Adapted from Bernstein, 2014. 
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1.4.4 Proteomics methods 
One of the two major approaches for profiling protein species and peptides is “Bottom-
up” proteomics which refers to the identification of amino acid sequences by analysis 
of peptides in proteolytic digests, and the assessment of these to determine which 
proteins are potentially present in a sample (Figure 1.9). The term bottom-up thus 
indicates that evidence about the potential constituent proteins is reassembled from 
individually identified fragment peptides (Wolters et al., 2001, Yates, 2004, Link et 
al., 1999). The major drawback of this approach is that only a small fraction of the 
total peptide population of a protein can be identified so there is low percentage 
sequence coverage (Tuli and Ressom, 2009). This poses a major problem in identifying 
all proteins of interest. The “top-down” approach enables separation of intact 
proteoforms and their subsequent identification and is therefore considered to be 
superior to the bottom up approach (Kelleher, 2004, Smith et al., 2013). Two-
dimensional gel electrophoresis (2DE) has been one of the mostly commonly used 
approaches to resolve proteoforms (Oliveira et al., 2014a) (Figure 1.9).  
A top-down proteomic approach utilizing 2DE coupled with liquid 
chromatography mass spectrometry/mass spectrometry (LC/MS/MS) was used in the 
current study to investigate first trimester serum protein species from women 
delivering spontaneously prior to 37 weeks’ gestation. This method of serum protein 
analysis was chosen because it is the only electrophoretic technique that can be 
routinely applied to quantitative expression profiling of large sets of complex protein 
mixtures such as serum. Additionally, 2DE facilitates a more complete total profiling 
including intact proteoforms reflecting the changes in abundance of the protein species 
present and thus retaining this critical biological/molecular information (Gorg et al., 
2000, Corbett et al., 1994, Oliveira et al., 2014b, Coorssen and Yergey, 2015). 
The technique of 2DE involves the separation of proteins from complex 
samples in accordance with two unique protein properties, namely iso-electric point 
(pI) and size (i.e. molecular weight; MW). The first dimension of separation is 
isoelectric focusing (IEF), which involves separation of proteins according to their pI 
on an immobilised pH gradient gel (O'Farrell, 1975). First dimension IEF is then 
coupled with second dimension sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE), to separate proteins by their MW resulting in the 
creation of a 2D proteome reference map of the proteoforms present (Laemmli, 1970). 
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After staining with colloidal Coomassie Brilliant Blue (cCBB) for total protein 
detection, the individual protein spots can be quantified and further analysed by MS 
(Gauci et al., 2013).  
 
 
 
 
 
Figure 1.9: Schematic representation of top-down and bottom-up proteomic 
approaches. Adapted from Switzart et al.,2013. 
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PTMs such as phosphorylation and glycosylation are identified using the 
fluorescent stains Pro-Q Diamond and Pro-Q Emerald, respectively (Orsatti et al., 
2009, Hart et al., 2003). Pro-Q Diamond and Pro-Q Emerald use a novel fluorophore 
to generate fluorescent signals by reacting with the phosphate and periodate-oxidized 
carbohydrate groups respectively. N-linked and O-linked processes represent the two 
major types of protein glycosylation. Reversible phosphorylation of serine, threonine 
or tyrosine residues, represents one of the most well-studied mechanisms of PTM 
(Lodish H, 2000, Humphrey et al., 2015). 
There is consistent evidence in the literature supporting the critical roles of 
glycoproteins in biological mechanisms and cellular processes (Stadlmann et al., 2017, 
Chen et al., 2013). Characterization of the glycome and glycoproteome can be 
challenging due to their complex nature (Jensen et al., 2012). Furthermore, the 
glycosylation machinery is sensitive to disease manifestations; this has, for example 
led to several groups suggesting that changes in glycan assembly could be promising 
candidate biomarkers (Ruhaak et al., 2013, Zhu et al., 2017, Thaysen-Andersen et al., 
2016). Even subtle changes in sugar structure such as a N-glycan core substitution by 
a single sugar moiety can have adverse functional consequences and be of potential 
value from a clinical perspective (Shah et al., 2015, Zhang et al., 2016, Haakensen et 
al., 2016, Brown et al., 2018).  
 
1.4.4.1 Deep imaging and third-dimension electrophoresis (3DE) 
Third dimension separation (3DE; ‘postfractionation’) is used to further resolve co-
migrating proteins that appear as hyper-abundant spots after initial resolution by 2DE, 
using a gradient gel customized to provide optimal resolution within the target 
molecular weight range (Butt and Coorssen, 2005, Wright et al., 2014b, D'Silva et al., 
2017). Deep imaging involves excising saturating spots/regions and re-imaging the gel 
at a higher photon-multiplier tube setting of 750 V, thus enabling detection of lower 
abundance proteins, that were originally below the level of detection (Wright et al., 
2014b, Wright et al., 2014a, Partridge et al., 2016, D'Silva et al., 2017). 
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1.4.4.2 Mass spectrometry 
Protein species of interest are excised from cCBB stained 2D gels and subjected to 
proteolytic cleavage with trypsin to generate peptides in solution. Peptides are ionized 
within a mass spectrometer to produce a measurement of their masses.  A number of 
ionization methods are used; peptides can be co-crystallized with a matrix for matrix 
assisted laser desorption/ionization (MALDI) (Duncan et al., 2008), or the liquid 
peptide mixture can be subjected to electrospray ionization (ESI) (Liuni and Wilson, 
2011). After ionization, peptides are detected within the spectrometer using time-of-
flight (TOF), quadrupole, ion trap, or fourier transform ion cyclotron resonance mass 
analysers (Signor and Boeri Erba, 2013). Mass spectrometers are designated by their 
combination of ionization method and mass analysers. MS/MS methods refer to 
multiple peptide fragmentation steps occurring within the mass spectrometer, 
generally within a single run, and provide a greater level of detail about peptide amino 
acid sequence not available from single fragmentation approaches like MALDI-TOF 
(Wysocki et al., 2005). This sequence information can be key in identifying the 
specific protein isoform of interest (Henzel et al., 2003).  
 
1.4.4.3 Quantitative image analysis 
The most important objective of proteomics is to identify differences in protein 
abundances (increase or decrease as assessed by spot intensity) between control and 
test samples. Once these protein spots have been identified using spot analysis 
software, the proteins of interest can be excised for identification using MS. 
Specialized software packages such as PDQuest (Bio-Rad), Melanie (GenBio), 
Delta2D (Decodon), Decyder 2D (GE Health) are used to analyse and quantify the 
changes in abundance of every protein spot by defining spot area boundaries and 
matching spots between gel images, and then comparing spot densities (i.e. via 
fluorescence or densitometry) (Rosengren et al., 2003, Kang et al., 2009). 
The image analysis for this study was performed using Delta2D V4.0 
(DECODON Gmbh, Greifswald, Germany), which is an alignment-based approach 
matching all preterm cases and control samples between the different gels (Millioni et 
al., 2010). Delta2D generates normalised average protein abundance levels for each 
individual spot from a warped gel image. Spots were deemed differentially abundant 
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and significant (one-way analysis of variance; ANOVA), when a  1.5-fold change in 
abundance was detected with a significance of p < 0.05. 
 
1.4.4.4 Bioinformatics 
Bioinformatics is the application of analytics and computational databases – for 
proteomics or any of the complementary omics - to assess and understand biological 
processes (Kumar and Mann, 2009). The most common protein database resources 
available to researchers for protein identification from MS data include the United 
Protein Database (UniProt, http://www.uniprot.org), which centralises three existing 
protein sequencing databases - SwissProt, Translational European Molecular Biology 
Laboratory (TrEMBL) and the Protein Information Resource - into one global 
resource. Other key protein database and analysis resources include the Mascot 
Daemon search algorithm. All these resources are aimed to provide free and 
unrestricted access to the most comprehensive and non-redundant information 
regarding protein structure and function. However, limitations of these latter resources 
must be considered when interpreting the results relative to the proteins experimentally 
identified. One such instance is the possibility of one spot containing 40-60 proteins 
and the ability of databases to identify the top-most hit i.e. protein of high abundance 
(Zhan et al., 2018). However, it is possible that apparent changes in protein abundance 
may be related to changes in other, lower abundance proteins associated with that spot.  
Additionally, pathway analysis software such as PANTHER (Protein Analysis 
Through Evolutionary Relationships) classification system, Reactome Pathway 
Database, STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) 
database and DAVID (the database for annotation, visualization and integrated 
discovery) enable at least an initial, provisional functional interpretation of large 
protein datasets, providing some first-pass guidance as to their biological context, 
involvement in various physiological pathways and association with disease 
pathophysiology.  
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1.4.5 The dynamic range challenge of serum  
Human serum proteins serve as a rich source of biomarkers as they reflect various 
physiological conditions at a given time point (Anderson et al., 2004). However, one 
of the greatest challenges in analysing the serum proteome is its complexity and wide 
dynamic range of concentration of individual proteins that extends from several 
milligrams to less than one pictogram per millilitre (Chandramouli and Qian, 2009). 
Furthermore, the high-abundance of certain protein species  tends to mask proteins of 
lower abundance, some of which might potentially be relevant to disease states 
(Millioni et al., 2011). 
Amongst the other highly abundant proteins, human serum albumin alone 
constitutes approximately 60% of the total serum proteome causing an overwhelming 
signal in detection assays (Guizado, 2014). Because of its high abundance, it plays a 
vital role in facilitating drug delivery (Larsen et al., 2016, Elsadek and Kratz, 2012). 
Human serum albumin can also undergo PTMs including glycation, S-guanylation and 
dehydroalanine conversion – the nature of the PTMs affects the ability of albumin to 
interact with drugs (Lee and Wu, 2015). Current research aims to utilize human serum 
albumin to improve efficiency of drug delivery and subsequent treatment of diseases 
(Lomis et al., 2016, Qi et al., 2016, Quan et al., 2011).  
Past research has focused on strategies to deplete human serum albumin for 
discovery of potential biomarkers that are often found in low abundance (Gianazza et 
al., 2016). However, studies have noted the presence of interesting molecules such as 
cytokines in the albumin depleted fractions (Granger et al., 2005). In general, the 
albumin-binding peptides and proteins are collectively called the albuminome (Liu et 
al., 2017). The albuminome has been suggested to be of value in identifying disease 
biomarkers when combined with other protein components (Lowenthal et al., 2005, 
Camaggi et al., 2010). 
Besides albumin, human serum also contains other highly abundant protein 
species: IgG, IgA, transferrin, haptoglobin, and antitrypsin. Collectively, these six 
abundant proteins constitute over 85% of the human serum proteome (Echan et al., 
2005). Depletion methods for highly abundant proteins have been widely investigated 
and a number of these have become commercially available (Polaskova et al., 2010, 
Bjorhall et al., 2005). These techniques include use of classical methods (Cibracon 
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Blue and protein A/G chromatography methods), immuno-affinity subtraction 
chromatography as well as various affinity spin tube filter, resins, and columns. The 
depletion strategies, however, are disadvantageous for two reasons: a) removal of the 
initially most abundant proteins merely exposes a second cohort that is highly 
abundant in comparison to other species; and b) these depletion methods lead to the 
concomitant removal of non-targeted protein species of interest (Bellei et al., 2011). 
Several critical assessments and refinements to better enable the resolution and 
comparison of serum proteomes were carried out as part of the research described in 
this thesis. The methods were then applied to identify first trimester maternal serum 
proteoforms between women who delivered spontaneously and those who delivered at 
term.  
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1.5 Previous attempts to identify protein biomarkers for preterm birth using 
proteomic approaches 
To date, many studies have documented the use of various proteomic approaches to 
predict preterm birth. Several biospecimens including cervico-vaginal fluid (CVF), 
amniotic fluid, saliva, plasma and placenta have been investigated to identify markers 
for preterm birth. However, none of the identified markers were found to be clinically 
effective for prediction of preterm delivery.  
A study examined the CVF to identify markers for preterm birth by using a gel 
based fluorescence 2D differential gel electrophoresis approach as well as a bottom-
up technique (Multidimensional Protein Identification Technology (MudPIT)) (Pereira 
et al., 2007).  Among the identified protein species, calgranulins, annexins, S100 
calcium-binding protein A7, and epidermal fatty acid binding protein were 
differentially abundant in sPTB and control samples. Interestingly, the group identified 
serum proteins (R-1-antitrypsin, R1-acid glycoprotein, haptoglobin, serotransferrin, 
and vitamin D binding protein) that were also differentially abundant in the CVF.  
The same group employed mass spectrometry and ELISA techniques to 
identify biomarkers of recurrent preterm birth in a larger cohort of at-risk women who 
underwent serial CVF sampling (Lo et al., 2014). The group identified 784 proteins in 
total, of which four proteins (Cysteine-rich secretory protein 3, Heat Shock Protein 
Beta-1, Protein S100-A7 and Alpha Enolase-1) were involved in the inflammatory 
cascade. However, ELISA analysis was unable to confirm the apparent altered 
expression of the candidate proteins.  
Another study cultured human columnar epithelial endocervical-1 and vaginal 
cells and utilized stable isotope labelling technology to generate labelled CVF 
proteomes in vitro (n = 5 preterm birth and n = 5 controls). The labelled secreted 
proteins from both cell lines were combined and characterized by LC/MS/MS. The 
group identified 1211 proteins in total and shortlisted 15 candidate proteins as potential 
preterm birth biomarkers previously linked to mechanisms underlying preterm birth. 
Furthermore, the group quantified 15 candidate proteins by employing multiple 
reaction monitoring (MRM) MS assay and demonstrated significantly increased levels 
of three proteins (desmoplakin isoform 1, stratifin, and thrombospondin 1 precursor) 
in women who delivered preterm (Shah et al., 2009).  
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An Australian group used 2D DIGE and MS to analyse the CVF proteome in 
symptomatic women who delivered preterm spontaneously and identified 12 proteins. 
Based on fold change and previous observations relating to human parturition, four 
proteins (albumin, IL‐1ra, thioredoxin and VDBP) were validated in a larger 
independent cohort of symptomatic women. ELISA analysis revealed significantly 
altered levels of albumin and VDBP in women who delivered preterm compared to 
term controls. When compared to fFN, a combined model of albumin/VDBP was 
found to be more effective to predict sPTB in symptomatic women within 7 days 
(Liong et al., 2015).  
Inflammatory biomarkers characteristic to HCA and funisitis (neutrophil 
defensins 2 and 1 and calgranulins C and A) have been identified in amniotic fluid 
using a proteomics approach (Buhimschi et al., 2009). Based on these findings, 
researchers sought to determine the relationship between identified inflammation 
associated biomarkers and cord blood IL-6 to assess the likelihood and severity of 
developing FIR. A direct correlation was seen between the AF and cord blood IL‐6 
levels; however, severity of infection could not be used to measure the intensity of 
FIR. 
The results obtained by Romero at al. suggest that mass spectrometric 
signatures of the amniotic fluid can be used to distinguish women delivering preterm 
due to intrauterine infection from women delivering without inflammation/infection at 
term (Romero et al., 2008). Another study used amniotic fluid in the mid-trimester of 
pregnancy to identify biomarkers via an LC/MS/MS approach in the exploratory 
phase. They identified six dysregulated proteins and suggested CRP as a marker to 
predict sPTB at 14-19 weeks’ gestation. However, the group was not able to validate 
their findings through ELISA (Hallingstrom et al., 2016).  
In recent years, research into microparticles has attracted much attention. 
Microparticles are a group of small bioactive vesicles released into the circulation due 
to stress, cellular damage or infection (Herring et al., 2013). Pregnancy associated 
microparticles are involved in cross-talk between maternal and fetal tissues and play 
crucial roles in various immune related pathways. Analysis of circulating 
microparticles in first trimester plasma samples identified several clinically significant 
protein mediators involved in the complement system and associated inflammatory 
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pathways (Cantonwine et al., 2016). Another study examined circulating 
microparticles in second trimester maternal serum and identified proteins associated 
with inflammation and cell injury to be predictive of sPTB (Ezrin et al., 2015).  
It has been hypothesized that even prior to the onset of clinical signs, there are 
differences in the maternal serum proteomic profile in women destined to deliver a 
premature baby (Esplin, 2014). A study utilizing an Electrospray-ionization, time-of-
flight mass spectrometry (EOI-TOFMS) technique to assess serum identified three 
peptides arising from inter-alpha-trypsin inhibitor heavy chain 4 protein to be 
significantly decreased in asymptomatic women at 24-28 weeks having subsequent 
sPTB. Nonetheless, the results do not allow for any confident differentiation of the 
three proposed biomarkers according to a potential aetiology for sPTB (Esplin et al., 
2011).  
Another study, employing shotgun proteomic approache, indicated that 
elevated levels of serpin B7 in maternal serum can be used as a predictive marker for 
sPTB in symptomatic women (Parry et al., 2014). A panel of 31 proteins were found 
to be in low abundance and only serpin B7 was found to be increased in serum samples 
from women who delivered preterm compared to women who delivered at term. The 
role of serpin B7 in the context of sPTB has not yet been studied. Consequently, 
validation studies in asymptomatic women to understand the mechanism of serpin B7 
in sPTB are warranted.  
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1.6 Hypothesis and Aims 
 
Hypothesis 
Differences in the serum proteomes of preterm or term pregnancies are present as early 
as 11-13+6 weeks’ gestation. These differences can be identified through proteomics 
and will likely prove to be of substantial value in predicting risk of spontaneous 
preterm birth, thus enabling early interventions that reduce or eliminate this risk in the 
future. 
 
Aims and Objectives 
 
➢ To test and refine methods for characterization of maternal serum protein 
profile using a top-down proteomic approach. 
 
➢ To characterise differential protein profiles and post translational 
modifications of the first trimester maternal serum proteome using a highly 
refined top-down proteomic approach based on 2DE coupled with mass 
spectrometry. 
 
➢ To validate candidate protein biomarkers by use of a western blot approach in 
a larger cohort of affected pregnancies and therefore identify protein markers 
that will be of value in the prediction of preterm labour. 
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Abstract: Serum provides a rich source of potential biomarker proteoforms. One of the major
obstacles in analysing serum proteomes is detecting lower abundance proteins owing to the presence
of hyper-abundant species (e.g., serum albumin and immunoglobulins). Although depletion
methods have been used to address this, these can lead to the concomitant removal of non-targeted
protein species, and thus raise issues of specificity, reproducibility, and the capacity for meaningful
quantitative analyses. Altering the native stoichiometry of the proteome components may thus
yield a more complex series of issues than dealing directly with the inherent complexity of the
sample. Hence, here we targeted method refinements so as to ensure optimum resolution of serum
proteomes via a top down two-dimensional gel electrophoresis (2DE) approach that enables the
routine assessment of proteoforms and is fully compatible with subsequent mass spectrometric
analyses. Testing included various fractionation and non-fractionation approaches. The data show
that resolving 500 µg protein on 17 cm 3–10 non-linear immobilised pH gradient strips in the first
dimension followed by second dimension resolution on 7–20% gradient gels with a combination
of lithium dodecyl sulfate (LDS) and sodium dodecyl sulfate (SDS) detergents markedly improves
the resolution and detection of proteoforms in serum. In addition, well established third dimension
electrophoretic separations in combination with deep imaging further contributed to the best available
resolution, detection, and thus quantitative top-down analysis of serum proteomes.
Keywords: deep Imaging; Lithium Dodecyl Sulfate; prefractionation; postfractionation; proteomics;
proteoforms; three-dimensional gel electrophoresis; two-dimensional gel electrophoresis
1. Introduction
Detailed analyses of the serum proteome are important as they provide a source of diagnostic
or prognostic biomarkers as well as insight into the mechanisms underlying disease development
and progression [1,2]. Due to the heterogeneity of disease, single protein markers are frequently
not sufficiently predictive of a condition to be of significant clinical value. A panel of candidate
biomarkers is typically needed to improve diagnostic efficacy [3,4]. Although fitness-for-purpose
must be considered in deciding between the use of bottom-up or top-down proteomic approaches [5],
quantification of disease-associated alterations is often best achieved by the latter, in which intact
proteoforms (i.e., protein species) are resolved from complex biological samples using techniques
such as 2-dimensional gel electrophoresis (2DE) coupled with mass spectrometry (MS) [6]. 2DE is
the only available proteomic technique that can simultaneously resolve hundreds-to-thousands of
Proteomes 2017, 5, 13; doi:10.3390/proteomes5020013 www.mdpi.com/journal/proteomes
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proteoforms in a single analytical run, while also enabling multiple parallel analyses. As the only such
routine top-down analytical protocol, it is thus the only available approach that enables quantitative
profiling of large sets of complex protein mixtures; that is, as part of the routine analytical protocol, this
approach resolves protein isoforms, splice variants, and the vast range of post-translationally modified
protein species that define biological functionality.
Serum contains one of the most complex proteomes that has thus far been researched. The dynamic
range of protein characteristics (e.g., isoelectric point, mass, hydrophobicity, concentration, and post-
translational modifications) makes effective coverage of the serum proteome very challenging as it
is difficult to resolve such a diverse range of macromolecules [7]. High-abundance proteins tend to
mask those of lower abundance and have typically been removed to allow better resolution of other
species [8]. However, removal of this fraction risks removal of non-targeted proteins that may impact
on our understanding of the mechanisms underlying disease as well as on discovery and quantification
of novel biomarkers [9]. In addition, removal of the most abundant proteins merely exposes a second
cohort that is highly abundant in comparison to other species—so this intervention fails to resolve the
fundamental problem of dynamic range and largely obviates the objective of quantitative analysis [5].
As with other complex samples, methods used to reduce the complexity of the serum proteome
are based on the physicochemical and structural characteristics of the constituent proteins, including
solubility, hydrophobicity, molecular weight and isoelectric point. Ultracentrifugation provides
a simple approach for the separation of high molecular weight proteins but is non-selective and thus
also does not address the issue of protein-protein binding and non-specific losses [10,11]. Similarly
trichloroacetic acid (TCA) has been used to precipitate high abundance proteins such as albumin by
forming a TCA-albumin complex [12]. Phase separation of detergents such as Triton X-114 (TX-114)
distinguishes between proteins on the basis of hydrophobicity and is relatively cheap and versatile but
the partitioning behaviour depends on the properties of the proteins being resolved (e.g., molecular
weight and surface exposure of different amino acid residues) and may still not fully address the issue
of non-specific protein losses to one fraction or the other [13]. Other methods are mainly used to target
the removal of hyper-abundant proteins and are based on affinity phases, ion-exchange and antigenic
activity [14]; these processes are similarly compromised by a lack of specificity and/or by the potential
of complex protein-protein interactions leading to the unintended removal of (lower abundance)
species bound to the highly abundant fraction. Whilst these techniques facilitate identification of
some less abundant proteins there is a risk that others will not be recognised and that any attempts at
quantification do not in fact represent the native state of the proteome.
In preparation for assessment of the serum proteomes of pregnant women who laboured preterm,
we have developed an analytic technique that does not remove protein species but nonetheless
enables improved differentiation of both high and low abundance proteoforms, of both high and
low molecular weight. As the whole serum proteome is conserved, the technique also allows
quantification of species, and for further future improvements as detection methods continue to
improve in sensitivity and selectivity [15–19]. In addition to the various techniques discussed and
tested in order to optimize efficient resolution of the native serum proteome, we have also combined
a robust and well-established 2DE protocol [20,21] with (i) a new, high sensitivity staining and detection
protocol [15,17,18]; (ii) postfrationation or third dimension electrophoresis (3DE) [22,23]; and (iii) Deep
Imaging [23–25]—as well as selective staining to assess phospo- and glycoprotein subproteomes
(i.e., proteoforms) in order to extract as much information as possible from each gel [9,24] (Figure 1).
3DE is used to further resolve co-migrating proteins that appear as hyper-abundant spots after initial
resolution by 2DE, using a gradient gel customized to provide optimal resolution within the target
molecular weight range [22,23]. Deep imaging involves excising saturating spots/regions and imaging
the gel at 750 V, thus enabling detection of lower abundance proteins [23–25]. We thus report the
development of an efficient, sensitive and reproducible technique that substantially improves the
quantitative protein profiling of native human serum, and that should prove widely applicable to
a range of comparable sample types including plasma and urine.
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2.1. Protein Assay
Protein estimation was performed using the EZQ Protein Quantitation Kit with BSA standards
according to the manufacturer’s instructions (Molecular Probes, Eugene, OR, USA). A baseline
native serum profile was prepared by solubilising crude serum in 2DE buffer containing 8 M urea,
2 M thiourea, 4% (w/v) CHAPS and a cocktail of protease, kinase and phosphatase inhibitors
(referred to as PI) at a ratio of 1× conc of PI (initial conc of 500×): 2 mL of serum [26].
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2.1.1. 2-Dimensional Gel Electrophoresis (2DE)
Proteins were resolved using a well-established protocol and further detail is provided in the
supplementary methods section [24]. Several methods of sample preparation prior to the first dimension
(termed phase I) and at the 2DE stage (termed phase II) were tested for potential improvements in
resolution whilst ensuring minimal loss of low abundant species and preservation of proteoform integrity
for quantitative assessment.
Phase I: Testing of fractionation techniques involved use of Ultracentrifugation, Trichloroacetic acid
(TCA) precipitation, Triton X-114 phase separation, Size exclusion filters, and the Aurum Affi-Gel Blue
column prior to the first dimension of resolution (Figure 1).
2.1.2. Ultracentrifugation
Considering the previously identified complement of membranous material and membrane
protein in serum and plasma [27,28], ultracentrifugation was carried out according to Churchward
et al., (2005) (supplementary methods) [29]. 2 mL of thawed serum with an added 1× conc of PI
was centrifuged at 146,542× g for three hours at 4 ◦C using a Beckman Coulter Optima L-100 XP
ultracentrifuge; the separate supernatant and pellet fractions were collected.
2.1.3. Trichloroacetic Acid (TCA) Precipitation
500 µL TCA (100% (w/v)) was added to 500 µL of crude serum and incubated at−30 ◦C overnight
(supplementary methods) [12]. The sample was centrifuged at 15,000× g for 30 min at 4 ◦C.
2.1.4. Triton X-114: Hydrophobic-Hydrophilic Phase Separation
TX-114 phase separation was carried out using a modification of the Bordier protocol [30]. In brief,
a cushion of 2000 µL of 6% (w/v) sucrose, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl and 0.5% TX-114
was placed at the bottom of a Falcon 15 mL conical centrifuge tube. 500 µL of crude serum sample
with 1 × PI was then overlaid on this cushion and the tube was incubated for 3 min at 30 ◦C to effect
condensation. The tube was centrifuged at RT for 3 min at 300× g to effect phase separation, yielding
a clear, viscous lower detergent phase (DP) and an upper aqueous phase (AP). After phase separation,
the DP and AP were analysed separately as described in the supplementary material.
2.1.5. Size Exclusion Filters
100 kDa and 50 kDa Amicon ultra-centrifugal low protein binding filter units (Merck Millipore,
Billerica, MA, USA) were briefly rinsed with 200 µL of 0.9% NaCl before use. 2 mL of crude serum
was mixed with an equal volume of saline containing 1× PI, and centrifuged in two stages (using the
100 kDa and 50 kDa filters, respectively) to produce three fractions of nominally > 100 kDa (fraction A),
50–100 kDa (fraction B) and < 50 kDa (fraction C); both centrifugation steps were carried out at 1008× g
for 20 min at 4 ◦C. Desalting and the estimation of protein concentration (both as above) were carried
out and all three fractions were then analysed by 2DE.
2.1.6. Aurum Affi-Gel Blue Column
The effect of albumin removal on analysis of the serum proteome was also tested using Aurum
affi-gel blue mini columns (Bio-Rad, Hercules, CA, USA). This protocol has been explained in the
supplementary material.
Phase II: Optimisation of ‘non-fractionation’ approaches involved using serum in the native form
for the first dimension while replacing or supplementing SDS with LDS for the second dimension
(Figure 1).
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2.1.7. Lithium Dodecyl Sulfate (LDS) vs. Sodium Dodecyl Sulfate (SDS)
We explored an alternative strategy to improving the resolution of protein species by resolving
native serum on large (i.e., 20 cm × 20 cm) 7–20% gradient acrylamide gels which enabled a larger
amount of protein to be resolved. LDS alone as well as a combination of LDS and SDS were tested by
first resolving native serum without any fractionation on 2D gels. LDS was added in the equilibration
buffer (6 M Urea, 20% glycerol, 375 mM Tris; pH 8.8, 0.1% LDS or a combination of 0.1% LDS and
0.1% SDS) when reducing and alkylating the IPG strip after IEF, as well as in the gel matrix (7% and
20% acrylamide, 375 mM Tris, 0.1% LDS or a combination of 0.1% LDS and 0.1% SDS) used in the
second resolving dimension (see supplementary material).
Phase III: Deep imaging and third-dimension electrophoresis (3DE).
Here, 2DE was combined with 3DE (a postfractionation approach) and integrated with
a well-established ‘deep imaging’ protocol [23–25]. For each 2DE analysis, 500 µg of protein
was resolved on 17 cm, 3–10 NL IPG strips, as described above; areas of near-saturating signal
(i.e., hyper-abundant proteins) were manually excised from the cCBB stained gels using a scalpel.
Imaging was repeated at 750 V for higher sensitivity protein detection. All excised spots were further
resolved using a standardized 3DE protocol. Briefly, those gels designated for 3DE were initially
stained using the reversible zinc-imidazole protocol [24], and saturating spots/regions were excised,
the zinc fixation reversed on both the main gel and the excised regions, and the latter were turned
90◦ relative to the initial path of resolution and then subjected to a third round of electrophoresis,
on narrow gradient gels customized to the corresponding molecular weight region; 10–15% for
heavy cut spots corresponding to 60–200 kDa and 15–18% for light cut spots corresponding to
10–50 kDa. Once electrophoresis was completed, gels were stained with cCBB, destained, and imaged
as described above.
2.2. Phospho and Glyco Staining
Pro-Q Diamond and Pro-Q Emerald stains were used to identify post translation modifications
(PTM), specifically, phosphorylation and glycosylation, respectively. Pro-Q Emerald 488 Glycoprotein
and Pro-Q Diamond Phosphoprotein stains were obtained from Life Technologies (Carlsbad, CA, USA).
Following 2DE, phospho- and glyco- staining was carried out on control serum sample according to
manufacturer’s protocols.
2.3. Image and Statistical Analyses
The resulting resolved protein spots from all 2DE and 3DE gels were quantitatively analysed
using automated spot detection in Delta 2D (version 4.08; DECODON GmbH, Greifswald, Germany).
For fractionation techniques, all images of replicate gels of both fractions were fused to create
a representative image. When serum was resolved, without any fractionation, mean spot counts
have been reported. Only protein species consistently and reproducibly detected across a given set
of replicate gels were considered for the spot count. These spot counts were obtained excluding
the gel edges and the protein ladder [24]. In order to examine the variation in protein spot numbers
following fractionation and alternate methods, the analysis of variance (ANOVA) with Tukey’s Multiple
Comparison Test was carried out.
3. Results
The mean spot count for the preliminary reference proteomes of native serum was 367± 2 for mini
gels and 709 ± 15 for large gels (Tables 1 and 2); this is ‘standard’ SDS-PAGE (2% SDS in equilibration
buffer and 0.1% SDS in resolving gel matrix) in the second dimension [29]. As well established in the
literature, larger gels with larger protein loads resulted in better resolution of proteoforms (p ≤ 0.001).
Proteomes 2017, 5, 13 6 of 16
Table 1. Total protein species resolved by 2DE after various methods of fractionation.
Methods Type of Gel Gel % ProteinConc.
Protein Species
Detected
Native serum (Baseline for statistical comparison)
Mini
12.5% 100 µg † 367 ± 2
Ultra 3 h 12.5% 100 µg 424 ± 21
Trichloroacetic acid (TCA) 12.5% 100 µg 358 ± 6
Tx-114 12.5% 100 µg 415 ± 3
Size exclusion filters
Frac A and Frac B (7–10%) 100 µg † 392 ± 24Frac C (12–20%)
Aurum Affi-Gel Blue column 12.5% 100 µg 285 ± 7
Tx-114 Large 7–20% 500 µg † 779 ± 51 *
Values given are average for total spot counts; all mean values were derived from combining fractions; n = 6 gels,
except † n = 4, Statistical significance indicated as * p ≤ 0.001; One way analysis of variance (ANOVA), Tukey’s
multiple comparison test.
Table 2. A comparison of the total number of protein species resolved using different 2DE and deep
imaging techniques.
Method Type of Gel Gel % ProteinConcentration
Number of Protein
Species Identified
Sodium dodecyl sulfate (SDS) (0.1%)
Large gel
12.5% 500 µg 709 ± 15No gradient (Baseline for statistical comparison)
SDS (0.1%) 7–20% 500 µg 864 ± 11 *
Lithium dodecyl sulfate (LDS) (0.1%) 7–20% 500 µg 870 ± 12 *
SDS (0.1%) + LDS (0.1%) 7–20% 500 µg 919 ± 15 *
Deep imaging
7–20% 500 µg 942 ± 7 *SDS (0.1%) + LDS (0.1%)
Values given are mean ± SEM for total spot counts; all mean values were derived from three technical replicates.
Statistical significance indicated as * p ≤ 0.001; One way ANOVA, Tukey’s multiple comparison test.
For the purpose of presentation, total protein species detected using each approach are given as
mean ± SEM (standard error of the mean) of the technical replicates. Individual mean ± SEM for
every fraction type are reported as supplementary data.
The spot counts and representative 2DE gels for the different methods of fractionation carried
out in phase I optimisation are shown in Table 1 and Figures 2–6, respectively. All fractionation
methodologies showed poor protein separation in terms of the molecular properties being targeted.
That is, there was considerable overlap in the distribution of protein species between fractions that
would have been expected to be far more distinct or defined based on the fractionation technique
used. The overlap between the fractions has been represented in the form of fusion images in the
supplementary material section. Ultracentrifugation (either 3 h or 16 h) was used to pellet a denser
protein fraction. The resolved 2DE gels indicated that a substantial portion of albumin was found in
the pellet fraction but most protein species were distributed across both the soluble and pellet fractions
(Figure 2). Following TCA/acetone precipitation of serum, the resulting 2DE gels of the pellet fraction
were better resolved to a certain extent; there was less streaking and a lower background than seen
after ultracentrifugation (Figure 3) and some less abundant species previously masked by albumin
were better resolved. However, the total number of protein species detected was reduced compared
to the native serum proteome (Table 1), and gels of the organic supernatant fraction suggested that
substantial amounts of proteins and charge variants other than albumin were lost using this protocol.
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In TX-114 phase separation, the AP did not provide effective separation of proteins, apparently
due to residual TX-114 (Figure 4). Incorporating multiple wash steps of the AP helped to remove
remaining TX-114 (Figure 4). The number of proteins resolved in AP and DP using TX-114 phase
separation was found to be significantly increased (p ≤ 0.001) compared to native serum (Table 1).
Though size exclusion filters performed well in promoting the overall resolution of proteins species
relative to the native serum gel, they did not appear to enable effective separation of protein species
of different size ranges, nor in limiting albumin to a single fraction. There was thus also substantial
evidence that low molecular weight proteins were retained in the high MW (>100 kda) fraction
(Figure 5). The commercial affinity columns also proved to be poor discriminators, removing a large
number of non-specifically bound proteins together with albumin (Figure 6). Overall, for these initial
12.5% mini gel tests, 3 h ultracentrifugation and TX-114 precipitation resulted in a significant increase
in protein species detected compared to native serum. Moreover, when resolved on a large gradient
gel of 7–20%, prior TX-114 phase separation resulted in the subsequent detection of 779 ± 51 spots in
comparison to 709 ± 15 (p ≤ 0.001) detected when analysing unfractionated native serum (Table 1).
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Bio-Rad Affi-Gel kit. Following manufacturer’s instructions, 100 µg of both bound and unbound
fractions were resolved on 12.5% acrylamide gels after undergoing isoelectric focusing on a 3–10 NL
IPG strip.
In this early stage of optimisation (i.e., phase I), most of the 2DE was carried out on mini gels.
However, there was a significant i crease in detectable protein species resolved on 7–20% gradient
gels rather than 12.5% gels i the second dimension (Tables 1 nd 2, d Figure 7). Henc phase II
optimisation was carried out on large, 7–20% gradient gels. Phase II optimisation involved resolving
native serum without any fractionation step. Table 2 documents a significant increase in the number
of protein spots resolved by using a combination of SDS (0.1%) and LDS (0.1%) as compared to the
classical SDS (0.1%) in the second dimension (Figure 7). Furthermore, deep imaging of the 0.1% SDS +
0.1% LDS gels resulted in a greater than 2-fold increase of resolved protein species compared to the
standard SDS alone (p ≤ 0.001) (Table 2, Figure 8). Third dimension separation of hyper-abundant
protein spots (particularly those known to correspond to albumin, immunoglobin heavy and light
chains, and serotransferrin) from serum proteomes initially resolved by 2DE enabled resolution of
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additional protein species from these more abundant co-migrating proteins (Figure 9). When fully
resolved by 3DE separation, the largest 2DE ‘spot’ (i.e., more of an irregular shaped, saturating
‘blotch’) was found to consist of more than one protein, clearly signifying that multiple species are
present in large and/or poorly resolved ‘spots’ (i.e., those not relatively small and tightly circular;
Figure 9) [22,24].
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Figure 7. Representative gel images sho i e fect of various det rgents on the resolution of
unfractionated serum: 500 µg total protein, 17 cm, 3–10 NL IPG, and 7–20% second dimension gradient
gel using 0.1% SDS (A), 0.1% LDS (B) and 0.1% SDS + 0.1% LDS (C).Proteomes 2017, 5, 13  11 of 17 
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Figure 8. Deep imaged serum proteome after excision of high abundance proteins (i.e., saturating
spots). 500 µg total protein, 17 cm, 3–10 NL IPG, and 7–20% second dimension gradient gel using
0.1% SDS + 0.1% LDS.
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Figure 9. Third-dimension separations of high-density (i.e., hyper-abundant) protein regions excised
from serum proteomes resolved by 2DE; red circles indicate protein species resolved from co-migrating
hyper-abundant proteins. Designations A-F refer to excised gel regions (see Figure 8), and in each
case the associated numbers refer to specific subsections of those excised gel pieces (i.e., A1-A3 means
excised region A was subdivided into three approximately equal sized gel pieces that were then
resolved in parallel on third gels (see Materials and Methods).
In addition to the general optimisation of serum analyses, we were also interested in PTM.
For confirmation at this stage, we thus also trialled the use of phospho- and glyco- staining as a first
analysis of select proteoforms (Figure 10).
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Figure 10. Phospho- and Glyco- proteome assessment: Control serum proteomes resolved by 2DE,
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4. Discussion
A variety of prefractionation methods have been developed to remove albumin and other high
abundance proteins from ser m samples prior to proteomic analysis thereby presumably enhancing the
detection of lower abundance speci s f potential in rest. H wever, this approa h could lead to the
concomitant removal of some on-target d proteins of potential scientific and clinical interest. We have
developed a routine technique for analysing the proteome of crude serum sa ples that does not
involve fractionation and therefore retains the native complement and stochiometry of protein species,
and fully enables quantitative analysis. Through systematic comparison of a variety of techniques,
we have shown that relatively heavy loading with 500 µg total serum protein on 17 cm 3–10 NL
IPG strips in the first dimension followed by second dimension resolution on 7–20% gradient gels
with a combination of LDS and SDS deterge ts provides the optimal current top-down ethodology
to res lve the human serum proteome. Our optimisati p o ess was carri d ut in three phases
(Figure 1). Phase I optimisation (fractionation) was carried out to reduce the complexity of serum
by restricting highly abundant proteins to one fraction. All of the commonly used prefractionation
techniques (phase I) that we tested showed substantial overlap in terms of protein content in the
separate fractions. This overlap indicates insufficient resolving power of these methods and increases
concerns that quantitative analysis using any of these methods is unlikely to yield satisfactory outcomes.
In phase II, w were able to obtai significantly increased numbers of resolved protein species by using
crude serum itself (Table 2 and Figure 7); this involved optimising 2DE with ut any fractionation and
hence no loss of proteins, in order to facilitate subsequent quantitative assessment. In addition to using
standard 2DE techniques for analysis we found that phase III, 3DE of highly abundant proteins, enabled
further resolution of co-migrating proteoforms, and Deep Imaging enabled further detection of lower
abundance species (Table 2, Figures 8 and 9) [17,23,24]. Use of selective phospho- and glycoprotein
stains confirmed the well-established ability of 2DE to routinely resolve proteoforms (Figure 10).
Whilst serum markers pla an important role i medical screening, many ave seemingly been
discovered somewhat endipi ously rather than through a systematic process of biomarker discovery.
The subsequent translation of biomarkers fr m discovery to clinical practice involves multiple stages
with many potential pitfalls. One major challenge is the inherent biological complexity of the serum
proteome [7]. To date, the majority of research directed to identifying serum biomarkers through
a top-down 2DE approach has involved the use of depletion columns to remove the most abundant
proteins. The traditional depletion strategy involves the use of a hydrophobic dye, Cibacron blue,
which has a high affinity for albumin. This strategy for removing albumin is frequently used in
proteomic analyses of serum because of its relatively low cost [31]. The use of immunoaffinity media,
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which consist of matrices with covalently attached antibodies to the most abundant proteins has also
become commonplace [32,33]. Antibody-based affinity chromatography techniques to remove albumin
have been established to isolate and investigate albumin-bound proteins [34]. Immunoglobulins G
represent the second most abundant protein species in serum and some methods have been established
to remove not only albumin, but also this class of proteins [35,36]. Methodologies based on the
depletion of high abundance proteins followed by liquid chromatography-mass spectrometry have
been used as well [37,38]. Combinatorial hexapeptide ligand libraries have also been used to enable
detection of low abundance proteins of interest [39,40]. This approach also works on the principle
of affinity chromatography and has been coupled with antibody based depletion methods to treat
human serum and other complex biological extracts [32,33,41,42]. However, a major a disadvantage
of this method is that in spite of the large number of ligands, if none has affinity for a given protein,
the latter will not be captured [39]. Furthermore, quantitative removal of any given species is not
ensured, and nonselective loss of proteins has also been documented, indicating similar selectivity
issues and concerns for later quantitative analyses as noted for other affinity-based fractionation
approaches [8,43,44]. Overall, the methods above are based on depletion of proteins to ‘reduce’ the
complexity of the serum proteome, usually with the aim of qualitatively detecting more proteins rather
than quantitatively identifying and confirming any given species as a biomarker.
However, these depletion strategies can lead to the concomitant non-specific removal of proteins
that may be of potential interest [8]. As a transport protein, albumin binds to various compounds
including hormones, lipids and amino acids so the loss of low-abundance peptides or small proteins
of interest, such as cytokines, is inevitable [45]. Stempfer et al., (2008) quantified the effectiveness of
human high-abundance serum and plasma protein depletion using 2DE and bottom-up shotgun MS
(i.e., 2D capillary chromatography with MS/MS). The data indicate that some low-abundance proteins
were still identified following the depletion protocol; nevertheless, on resolving the depleted fractions,
several proteins were found to adhere to the depletion matrix and were thus completely lost to
analysis [46]. In brief, these methods have a clear shortcoming in terms of the loss of potentially critical
protein species that could be of translational significance in a clinical setting and/or to understanding
disease mechanisms, and thus also hamper or even obviate the quantitative analyses necessary to
establish the importance of such disease markers or effectors.
Sample preparation is a critical step in the proteomics workflow as the quality and reproducibility
of protein extraction and handling significantly impact coverage and quantitative analysis of the
native proteome. Minimising sample preparation avoids proteoform degradation and modification.
Most of the prefractionation methods we assessed involved several steps and resulted in unexplained
variations in analyses of the same samples, including substantial overlap of protein species (i.e., poor
separation) between fractions (Figures 2–6). In contrast, starting with 500 µg serum protein on
3–10 NL IPG strips in the first dimension followed by second dimension resolution on a large 7–20%
gradient gel by SDS/LDS PAGE improved the resolution and detection of protein species (Table 2).
Little is known about the mechanism by which LDS and SDS in combination contribute to protein
resolution, although it is well documented that LDS promotes the solubilization and resolution of
certain hydrophobic proteins, particularly under the temperature conditions used in our established
protocol (i.e., 4◦C) [47–49]. In this study, in particular, low molecular mass protein species were
strongly enriched using a combination of SDS and LDS confirming what has been previously noted
in the literature [50]. Furthermore, adding LDS pre- and post-second dimension of electrophoresis
(i.e., in the equilibrating buffer, the gel matrix, and the 2D buffer system) enabled resolution of certain
proteins not detectable when using SDS or LDS alone (Table 2). We also confirm the resolution of
proteoforms using selective staining for phospho- and glycoproteins (Figure 10).
5. Conclusions
When selecting a prefractionation method to assist in sample preparation, it is imperative to assess
the potential for loss of low abundance proteins; the possibility of carrier protein interactions with
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critical low molecular weight biomarkers is likely a serious issue hampering further advances. Most
studies that have investigated the serum proteome in various disease conditions have not been able
to successfully characterize potential biomarkers nor validate their results in a larger cohort. Simply,
altering the native stoichiometry of the proteome components may yield a more complex series of
issues than dealing directly with the inherent complexity of the sample. This is the fundamental basis
for our focus on top-down proteomic analyses of native samples.
In terms of the current investigation, maternal serum samples were pooled from three individual
patients in order to evaluate methods and develop an analytical process. The method developed
in this study is now being routinely applied to clinical samples. We will be applying the approach
defined here to further characterize and quantify protein species in a larger cohort of subjects to
provide a better understanding of the maternal serum proteome. One of the potential limitations of
the results presented here was the need to ‘over’-load the gel with 500 µg protein in order to assess
lower abundance species (although this only amounts to an average of ~10 µL of serum). While this
would not be an issue for several standard clinical samples (e.g., plasma, urine, saliva), it may not be
feasible with regard to other health complications [5]. Importantly, the advantages of the approach
defined here cannot be overstated: quantitative analysis of protein species in their native melieu
(i.e., without exposure to fractionation and other chemical manipulations). It is expected that this
represents an opportunity for broader use of this critical top-down approach to proteomic analyses
of serum and other important clinical samples. We anticipate that this top-down 2DE approach will
prove to be a powerful tool for quantitative, reproducible and thorough analyses of proteoforms,
and thus imperative to assessing health, disease state and progression, as well as the identification of
critical biomarkers.
Supplementary Materials: Supplementary Materials are available online.
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Abstract  
Spontaneous preterm birth is the leading cause of perinatal morbidity and mortality worldwide 
and continues to present a major clinical dilemma. We previously reported that a number of 
protein species were dysregulated in maternal serum collected at 11-13+6 weeks’ gestation 
from pregnancies that continued to labour spontaneously and deliver preterm. In this study, 
we aimed to validate changes seen in four candidate protein species: Alpha-1-antitrypsin, 
Vitamin D-binding protein, Alpha-1 beta-glycoprotein and Apolipoprotein A-1 in a larger cohort 
of women using a western blot approach. Serum levels of all four proteins were reduced in 
women who laboured spontaneously and delivered preterm. This reduction was significant for 
Vitamin D-binding protein (p=0.04), which has been shown to be involved in a plethora of 
essential biological functions, including actin scavenging, fatty acid transport, macrophage 
activation and chemotaxis. The decrease in select proteoforms of Vitamin D-binding protein 
may result in an imbalance in the optimal intrauterine environment for the developing fetus as 
well as to a successful uncomplicated pregnancy. Thus, certain (phosphorylated) species of 
Vitamin D-binding protein may be of value in developing a targeted approach to the early 
prediction of spontaneous preterm labour. Importantly, this study raises the importance of a 
focus on proteoforms and the need for any biomarker validation process to most effectively 
take these into account rather than the more widespread practice of simply focussing on the 
primary amino acid sequence of a protein.  
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Introduction  
Spontaneous preterm birth (sPTB), defined as spontaneous birth before 37 weeks’ gestation, 
is the most significant problem affecting contemporary obstetric practice and is recognised as 
a major health concern worldwide (1-4). 15 million babies are born preterm each year and 
prematurity is described as the cause of death in 10% of stillbirths and 40% of neonatal deaths 
(5). Preterm infants are >20 times more likely to require neonatal admission than term babies 
and these infants suffer significant short and long term morbidity (6). Despite considerable 
effort, the incidence of preterm birth is still rising (7). Given the complex and poorly 
characterized pathophysiological pathways associated with preterm birth, its prediction has 
been a challenge. As a result, almost every preterm event is an emergency, adding further 
stress to mother and fetus, as well as healthcare systems. 
 
Current strategies for prediction and prevention of preterm birth focus on identification of, and 
intervention in, a high-risk cohort in the second or third trimester of pregnancy (8-10). 
Screening tools such as ultrasound assessment of cervical length require significant capital 
investment and the availability of trained staff but have modest screening efficacy (11). 
Women deemed to be at high-risk of spontaneous preterm birth may be prescribed 
preventative therapies such as progesterone, but this does not prevent all cases of prematurity 
and there is some controversy about the impact of preventative interventions at this relatively 
late stage (12, 13). There are far fewer data describing first trimester models for risk prediction 
and these are currently less effective than second / third trimester counterparts (14). Cervical 
length is often used in these models but is harder to assess earlier in gestation due to apparent 
continuity with the lower uterine segment. Multivariate algorithms that involve combinations of 
maternal history and other investigational tools have shown only moderate levels of efficacy 
in screening for sPTB (15, 16). Given that current screening strategies have not made a 
significant impact on preterm delivery rates, there is an urgent need to improve our 
understanding of the molecular mechanisms underlying preterm birth and to identify and 
develop other biomarkers that can be assessed early in pregnancy, enabling more timely and 
effective preventative action. 
 
Current proteomic approaches enable comprehensive surveys of low- and high-abundance 
proteins in tissues and various biological fluids. Notably, as protein species or proteoforms 
(i.e. isoforms, splice variants, and post-translationally modified forms) are generally the 
effectors of biological mechanisms, it is critical to employ an analytical approach that can 
effectively resolve proteomes without loss of the important information embodied by this 
diverse group of molecules (17-19). Thus, in order to identify protein species that may be of 
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value in identifying pregnancies at risk of preterm birth, we used a refined top-down proteomic 
approach coupling two-dimensional gel electrophoresis (2DE) and liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) to characterise differential 
proteoform profiles in first trimester maternal serum (20, 21). In contrast to other analytical 
approaches, the 2DE/LC/MS/MS approach can simultaneously resolve hundreds-to-
thousands of proteoforms in a single analytical run and enables identification of species 
undergoing changes in abundance. In an initial analysis of serum (20), thirty proteoforms were 
found to be significantly altered at 12 weeks of gestation in a group of women who 
subsequently experienced sPTB relative to a matched group who experienced normal term 
delivery. The distinguishing proteoforms included Alpha-1-antitrypsin (A1AT), Vitamin D-
binding protein (VDBP), Alpha-1beta-glycoprotein (A1BG) and Apolipoprotein A-1 (ApoA1) 
that had previously been described in pathways associated with preterm birth. In the current 
targeted analysis, we sought to validate whether these protein species were similarly altered 
in a second, larger cohort of patients that subsequently delivered preterm after spontaneous 
onset of labour.  
 
Materials and methods 
Study design 
Proteomic analyses were carried out on a cohort of maternal serum samples prospectively 
collected and stored during first trimester screening at 11-13+6 weeks’ gestation. The samples 
were collected between 2011 and 2014 and serum was separated within four hours of 
collection. Aliquots of residual serum, available after measurement of free βhCG and PaPP-
A, were stored immediately at -80°C. Details of pregnancy outcome were collated at the end 
of pregnancy allowing identification of a cohort of women who laboured spontaneously and 
delivered before 37 weeks’ gestation (n = 44). These were matched (one to one) to a cohort 
of women who laboured spontaneously and delivered at term (>37 weeks’ gestation) (n = 44). 
Note, this total cohort also included serum samples from the original 10 sPTB and 10 term 
delivery cases analysed using 2DE/LC/MS/MS (20). Control samples were matched by 
maternal age, gestational age, BMI, parity, smoking status, sex of the fetus and sample 
storage time. Samples were excluded if preterm delivery was elective, had occurred after 
spontaneous rupture of membranes or involved a multiple pregnancy or a pregnancy affected 
by chromosomal or structural abnormality. The study was approved by the local hospital 
Human Ethics Committee (Protocol No: X11-0305). 
Differences in abundance of select serum proteins identified in an earlier initial quantitative 
proteomic analysis (20) were validated further using a well-established, high sensitivity 
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western blotting approach. Selection of the proteins for validation was based on fold-changes 
in abundance (from the original 2DE assessments) and possible functional association of the 
proteins with PTB as documented in the literature (20). Western blot analyses of four 
differentially expressed target proteins ― Alpha 1-antitrypsin, Vitamin D-binding protein, 
Alpha-1beta-glycoprotein and Apolipoprotein A-1 ― were carried out on serum samples from 
the 44 sPTB patients and 44 matched term controls described above.  
 
Antibodies  
Primary antibodies: Monoclonal rabbit [EPR17087-50] to Alpha-1-antitrypsin (ab207303), 
monoclonal rabbit [EP2923Y] to Vitamin D-binding protein (ab81307) and monoclonal rabbit 
[EPR9830(B)] to Alpha-1beta-glycoprotein (ab156009) were purchased from Abcam Australia 
Pty Ltd, Melbourne, Australia. Monoclonal mouse Apolipoprotein A-1 (B-10) (SC-376818) was 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). These antibodies are 
hereafter referred to as ab207303, ab81307, ab156009 and SC-376818, respectively. 
Secondary Antibodies: Goat Anti-Rabbit IgG heavy and light (H&L) conjugated to Horseradish 
Peroxidase (HRP) (ab97051) was purchased from Abcam Australia and was used to detect 
ab207303, ab81307 and ab156009. Mouse IgG kappa binding protein (m-IgGκ BP) 
conjugated to HRP (SC-516102) was purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA) and was used to detect SC-376818. All antibodies were stored and handled 
according to the manufacturer’s instructions. 
 
1-Dimensional gel electrophoresis (1D SDS-PAGE) 
Crude maternal serum with added protease, kinase and phosphatase inhibitors (21) at a ratio 
of 1 × conc of inhibitors (initial conc of 500 ×) : 2 mL of serum was diluted in 1 x Phosphate 
buffered saline (PBS) and solubilized in 2 x sample buffer (Laemmli 2 x concentrate (Tris 0.5 
M, pH 6.8,  Glycerol 20% (v/v), EGTA 6 mM (w/v), SDS 4% (w/v), bromophenol blue 0.001% 
(w/v), β-mercaptoethanol 0.2% (v/v), added 1:1 just prior to use)) and heated at 100ºC for 5 
min. The total protein concentration of each sample was determined using the EZQ Protein 
Quantitation Kit with BSA standards according to the manufacturer’s instructions (Molecular 
Probes, Oregon, USA). A final concentration of 5 µg total protein in 20 µL was loaded onto 
each lane of 8 – 16 % SDS polyacrylamide mini electrophoresis gels (10 x 8 cm SDS-PAGE) 
for Alpha-1-antitrypsin; 10 % mini SDS-PAGE was used to resolve Vitamin D-binding protein, 
Alpha-1beta-glycoprotein and Apolipoprotein A-1, respectively. The samples were also 
randomized to ensure that replicates of any given sample were not resolved on the same gel. 
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The gels were resolved at 100 V in SDS running buffer at 4ºC. All gels and thus subsequent 
immunoblots were replicated at least in triplicate. 
 
Western blot 
Western blotting was carried out essentially as previously described (22). Briefly, after 
completion of SDS-PAGE, proteins were electrophorectically wet-transferred using 1 x 
transfer buffer (Glycine 192 mM, Tris 25 mM, methanol 20%) at 100V to a 0.2 µm pore size 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA) for 2 hrs at 4ºC, 
thereby immobilizing the separated proteins. Post transfer, the PVDF membrane was blocked 
in TBST buffer (Tris 10 mM pH 7.4, NaCl 150 mM, 0.1% Tween 20) containing 5% skim milk 
powder (Woolworths brand) and 1% polyvinylpyrrolidone (PVP-40) for 1 hr at room 
temperature (RT) on a shaker, and subsequently washed with TBST 3 x 15 min. Primary 
antibodies [(ab207303 1:5000 dilution), (ab81307 1: 5000 dilution), (ab156009 1:5000), (SC-
376818 1: 500 dilution)] were applied to the blots and incubated overnight at 4ºC (~16 hrs). 
The following day, blots were washed with TBST buffer 3 x 5 min and incubated with HRP 
conjugated secondary antibodies [(ab97051 1: 25,000 dilution), (SC-516102 1: 1000 dilution)] 
for one hour at RT on a shaker. After secondary incubation, the blots were washed with TBST 
3 x 10 min followed by TBS for 10 min and protein bands were developed using the Enhanced 
chemiluminescence (ECL) Plus detection kit (GE Healthcare). The immunoblots were 
scanned and florescence signals measured using the LAS 4000 Biomolecular Imager, and the 
integrated pixels was quantified using Multi Gauge software v3.0 ((FUJIFILM, Tokyo, Japan). 
Images were captured using high resolution sensitivity and 5 s ‘precision’ exposure, at tray 
positions TP 1 – 4, for ab207303, ab81307, ab156009 and 2 s exposures for SC-376818, at 
tray positions 1 – 4.  
Each patient sample was resolved in triplicate for every antibody. All western blots were 
imaged individually. A series of prior optimizations were carried out for each antibody. This 
included optimizing protein load (i.e. ensuring that signal did not saturate and thus changes in 
signal intensity (i.e. protein abundance) could be readily and consistently detected), 
percentage of acrylamide gel, transfer time, primary and secondary antibody dilutions and 
incubation time for probing with the primary antibodies (Figure 1). Additionally, secondary 
antibody controls were carried out in parallel for each antibody and, after electrophoretic 
blotting, SDS-PAGE gels were stained and assessed using a protocol providing low-to-sub-
femtomole detection of proteins (Figure 2) (23, 24); relative to identical control gels that had 
not undergone blotting, these confirmed a consistent transfer efficiency of ~95% for each of 
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the target proteins (Figure 3). Total lane scans of random control gels (i.e. not blotted) also 
confirmed consistency of total protein load per lane and thus overall normalization of loading.  
 
 
Figure 1: Representative immunoblot images of full lanes of Alpha 1-antitrypsin, Vitamin D-binding 
protein, Alpha-1beta-glycoprotein and Apolipoprotein A-1 to indicate selectivity of bands. 
 
 
Figure 2: Representative images for secondary antibody; Goat Anti-Rabbit IgG and Mouse IgG 
kappa binding protein 
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Figure 3: A stained gel before and after transfer with the areas of interest indicated 
 
Image analysis 
Multi Gauge software was used for densitometric analyses of western blots. A rectangular box 
was created for each band of interest using the ‘rectangular select tool’. Per band, background 
measurements of equivalent total area were taken from ‘clear’ or ‘blank’ regions of the blot, 
beneath the band of interest. Resulting raw data were analysed in Excel (Microsoft office, 
2016) to obtain background subtracted final values for every protein.  
 
Statistical analysis 
Comparisons between the term and preterm groups were made in Graph Pad Prism v7.03 
using Paired t-tests. A value of p < 0.05 (*) was considered statistically significant, and 
p < 0.01 (**) was considered highly statistically significant. Data are presented as the mean 
± standard error mean (SEM). Each result represents data from three independent western 
blots for each sample. The groups were tested for normal distribution using Wilcoxon’s 
signed ranked test. Pairwise comparisons were carried out using SPSS statistics software 
v24.0 after adjusting for maternal age, BMI, ethnicity and parity.  
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Results  
88 first trimester serum samples (44 from pregnancies that delivered after the spontaneous 
onset of labour <37 weeks gestation and 44 from pregnancies that delivered >37 weeks 
gestation) were analysed here using a high sensitivity western blot approach. This included 
the 10 sPTB and 10 terms samples used in our discovery phase (20). Demographic and 
clinical characteristics of these samples are presented in Table 1. The only significant 
difference between sPTB cases and controls were the gestational age at delivery (p=0.0001) 
and birthweight (p=0.0001), as was the case in the initial biomarker discovery study (20).  
 
 
Table 1: Baseline characteristics of original and validation cohorts; sPTB vs term control pregnancies. 
 
Values have been represented as mean ± SEM or %, statistical analysis involved an unpaired t test. * Denotes 
statistical significance 
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Representative western blot images for Alpha-1-antitrypsin, Vitamin D-binding protein, Alpha-
1beta-glycoprotein and Apolipoprotein A-1 immuno-reactive bands are shown in Figure 4. 
Statistical analyses of these data indicated a significant reduction in levels of Vitamin D-
binding protein in the sPTB cohort compared to the term controls (27.8 ± 1.7 vs. 30.8 ± 2; p = 
0.04 (Table 2; Figures 4 and 5). There were no significant differences in the serum 
concentrations of the remaining three candidate proteins (Table 2; Figures 4 and 5).   
 
Table 2: Western blot analyses of selected proteins in women who subsequently had a sPTB vs. full 
term birth controls 
 
 
Intensities (arbitrary units) of immuno-blot bands; (mean ± SEM) 
 
 
 
Figure 4: Representative immunoblot images of Alpha 1-antitrypsin, Vitamin D-binding protein, Alpha-
1beta-glycoprotein and Apolipoprotein A-1 in control and sPTB. 5 µg of total protein was loaded per 
lane. 
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Figure 5: Representative graphs showing levels of Alpha 1-antitrypsin, Vitamin D-binding protein, 
Alpha-1beta-glycoprotein and Apolipoprotein A-1 in serum from sPTB and matched controls. 
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Further analysis of the data, allowing for differences in maternal age, BMI, parity, ethnicity and 
sex of fetus did not reveal any significant differences in protein levels between preterm cases 
and controls (Table 3). Statistical analysis accounting for maternal factors identified significant 
differences of Alpha-1-antitrypsin relative to ethnicity (Table 3). Women of South East Asian 
background had the highest levels of Alpha-1-antitrypsin, followed by Caucasians and East 
Asians (Table 3). Levels of Vitamin D-binding protein were significantly different comparing 
Caucasian and East Asian women (p=0.017); Caucasians had a 33% higher level. Maternal 
age appeared to be inversley correlated with Apolipoprotein A-1, but this did not reach 
significance (p = 0.056). Serum concentrations of Alpha-1beta-glycoprotein were reduced in 
nulliparous women (p=0.058) and there was an inverse relationship between Alpha-1beta-
glycoprotein and BMI (Table 3; p=0.044). Assessment of combinations of protein species after 
adjusting for maternal age, BMI, parity and ethnicity, did not identify any significant differences 
in protein levels between sPTB cases and matched term controls (Table 4).  
 
Table 3: Parameter estimates of Alpha-1-antitrypsin, Vitamin D-binding protein, Alpha-1beta-
glycoprotein and Apolipoprotein A-1 in relation to maternal characteristics 
*For the purpose of this presentation, only findings that reached significance or close to significance are reported. 
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Table 4: The effect of case status on combined protein expression, while adjusting for maternal age, 
BMI, parity and ethnicity 
pv = p-value, coef = the effect of being a case on the sum of given proteins  
 
Discussion 
We carried out a larger-scale validation study concerning previous findings identifying altered 
abundance of four protein species that appeared to be strong candidates as first trimester 
serum biomarkers for subsequent spontaneous preterm labour. Only one of these four 
proteins, Vitamin D-binding protein, showed a significant change in abundance in this 
validation cohort. Interestingly, this involved a decrease in the abundance of Vitamin D-binding 
protein whereas our smaller discovery data set had suggested an increase in the amount of 
some proteoforms and a decrease in a phosphorylated species. The broader implications of 
these findings to biomarker identification and validation studies are discussed.  
 
Vitamin D-binding protein, a 56–58 kDa plasma alpha-globulin, binds vitamin D and promotes 
actin clearance during tissue remodelling following the augmentation of the pro-inflammatory 
response (25). Serum concentrations of both vitamin D and Vitamin D-binding protein are 
typically increased in pregnancy (26). Dysregulation of both total serum Vitamin D levels and 
of Vitamin D-binding protein have been associated with adverse pregnancy outcomes such 
as pre-eclampsia, intrauterine growth restriction, gestational diabetes and preterm birth (27-
31).  
 
Evidence regarding associations between plasma concentrations of Vitamin D-binding protein 
and pregnancy complications is conflicting. Kolialexi et al. (2017) analysed first trimester 
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maternal plasma using 2DE and MALDI-TOF-TOF MS/MS to identify biomarkers for early 
onset preeclampsia (ePET). They identified 12 differentially expressed proteins, including 
Vitamin D-binding protein, which showed 3.4 fold up-regulation (32). In contrast, Tannetta et 
al. (2014) who investigated the actin scavenging system in pre-eclampsia, showed that plasma 
levels of actin-free Vitamin D-binding protein (measured using an ELISA immunoassay) 
tended to be lower in ePET pregnancies (33). The authors suggested that these findings were 
associated with depleted actin clearance and could be associated as a cause or a 
consequence of preeclampsia pathophysiology. A third study, by Powe et al. (2010), showed 
no significant difference in first trimester concentrations of Vitamin D-binding protein 
(measured using ELISA) between preeclamptic and control cohorts (29).  
 
Although there are no studies reporting changes in Vitamin D-binding protein concentrations 
in maternal blood specifically related to preterm labour, analysis of the proteome of cervical 
secretions has shown an increase in Vitamin D-binding protein in women that deliver preterm 
(34). In a second study, Liong et al. (2013) concluded that assessment of cervical swabs for 
Vitamin D-binding protein could be a useful predictor in women presenting with threatened 
preterm labour with sensitivity and specificity of 58.5% and 98.6% respectively (35). As 
Vitamin D-binding protein protects against vascular dysfunction and modulates the 
inflammatory response it is not unreasonable to anticipate that it will be altered in pregnancies 
that deliver preterm. The precise nature of the metabolic effect(s) mediated by VDBP require 
further elucidation and there needs to be more work to identify its importance in this field. 
 
There are several reasons why we may not have been able to validate apparent changes in 
protein abundance associated with subsequent onset of sPTB in the remaining three proteins 
examined in this study, and why the validation of VDBP does not fully correlate with our 
previous findings. The cohort of women included in this study delivered a mean of three weeks 
later than those included in the original cohort. Similarly, this cohort included women from a 
wider range of ethnic backgrounds than the original cohort. There is also increasing evidence 
indicating that 2DE gel spots do not necessarily contain a single protein species; more 
sensitive mass spectrometry may identify 40-60 proteins from one spot (36). The proteins 
assessed in this paper were originally identified through a 2DE/LC/MS/MS approach which 
included the criteria of high mascot scores, unique peptides and acceptable sequence 
coverage. It is however possible that apparent changes in protein abundance may have been 
related to changes in other, lower abundance proteins associated with that spot. Alternatively, 
like perhaps all previous studies in this and other areas, the immunodetection analysis used 
(e.g. western blot here; ELISA in many other studies) may have failed to adequately identify 
critical proteoforms (e.g. specific post-translationally modified species) as the antibodies used 
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in these assays may or may not differentiate between species and/or may be differentially 
selective depending on the type and location of different modifications (e.g. phosphorylated or 
glycosylated moieties).  
 
Thus, using VDBP as an example, the antibody used here clearly detects a prominent band 
on 1D gels at a MW consistent with the amino acid sequence of the protein. Small chemical 
modifications such as phosphorylation will not significantly change the MW of the protein as it 
resolves on a 1D gel (although will shift the pI on a 2D gel and will be particularly detectable 
if there is more than one phosphate group attached); potentially larger PTM such as large 
sugar moieties may however also result in detectable shifts in MW on 1D gels. However, 
depending on the location of any particular PTM (and likely its size as well), these may interfere 
with antibody binding. It is thus noteworthy that in our original study, VDBP was identified from 
three separate spots following high resolution 2DE (20). In the first instance VDBP was 
detected based on total protein staining, but this species was substantially more acidic than 
what is theoretically expected based on the amino acid sequence alone, implying substantial 
PTM such as multiple phosphorylations (20). Indeed, there are multiple phosphorylation sites 
as well as other PTM associated with VDBP, including a known glycosylation, and at least two 
isoforms of VDBP are produced by alternative splicing. Thus, it is not surprising that our high 
resolution 2DE protocol also identified both phosphorylated and glycosylated proteoforms of 
VDBP and found changes associated with sPTB: while the glycosylated proteoform and those 
detected with total protein staining were found to increase in sPTB cases, at least one (or 
more) phosphorylated species was found to decrease significantly in the first trimester serum 
of women who subsequently experienced a case of sPTB (20).  
 
Taking all this information into consideration, it would seem that at least some phosphorylated 
proteoforms of VDBP (which would be unlikely to resolve as separate bands on a 1D gel) are 
already sufficiently decreased in abundance in the first trimester serum of women who 
subsequently experience sPTB to yield detectable differences in the high sensitivity western 
blot assay used here.  That is, these phosphorylated proteoforms are of sufficient abundance 
that their detection outweighs the detection of other, unphosphorylated VDBP species that 
undoubtedly also resolve in the same gel band. This suggests the existence of one or more 
phosphorylated VDBP species that may well prove to be highly sensitive and selective early 
serum biomarkers for sPTB. This also raises the concern that lack of validation of the other 
three potential biomarker proteins assessed in this study may well rest with the antibodies and 
choice of assay used (i.e. lower resolution 1D gels). Are some proteoforms that are not 
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selectively associated with sPTB simply of higher abundance than some that are, and the 
result in an overall ‘average’ 1D western blot signal that is not significantly different between 
the control and sPTB study cohorts? The same result would also occur using commercial 
ELISA assays since most commercial antibodies are selected for their ability to detect a 
protein of interest rather than a specific proteoform (although there are of course exceptions, 
including antibodies to specific phosphorylated variants of proteins). Would an antibody 
selective for a PTM modified species of these proteins and/or the use of higher resolution 2DE 
rather than 1DE have resulted in confirmation of another potential biomarker or at least clear-
cut data eliminating a candidate? These are specific directions that will be addressed in future 
studies. 
 
Importantly, for this and any other biomarker studies in any field, these findings raise critical 
issues regarding the quality of up-front (i.e. initial) analyses and thus detection of meaningful 
molecular species, as well as the need for rigour in the validation process, with far more 
stringent attention to potentially critical proteoforms rather than simply the amino acid 
sequence of a protein in a database. Post-translational modifications may well hold the key to 
more successful identification and validation of critical biomarkers. Thus, spontaneous 
preterm birth continues to be a significant public health problem and the development of a first 
trimester predictive test that allows modification of pregnancy outcome remains a research 
priority. The abundance of different proteoforms of Vitamin D-binding protein, in particular 
phosphorylated species, appear to be significantly altered in these pregnancies and these 
may prove to be a valuable biomarker for the prediction of spontaneous preterm birth. Further 
identification and validation studies to define critical proteoforms across different ethnic groups 
are needed to most fully investigate the regulatory and immune functions of Vitamin D-binding 
protein species and which could serve as sensitive and selective early biomarkers for 
spontaneous preterm birth.  
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Summary of this work 
Preterm birth is the commonest adverse pregnancy outcome, affecting 8% of 
Australian pregnancies (Li Z, 2013). It is associated with increased rates of fetal 
mortality and morbidity. Rates of preterm birth have not reduced significantly over the 
last 20-30 years. In some countries rates have, in fact, increased (Blencowe et al., 2012, 
Liu et al., 2016). One approach to reducing the prevalence of preterm birth involves 
early prediction of high-risk pregnancies that would potentially benefit from 
preventative intervention. Such a process, involving screening at 12 weeks’ gestation, 
has been successful in predicting and preventing other pregnancy complications such 
as preeclampsia (Anderson et al., 2015, Poon and Nicolaides, 2014, Rolnik et al., 
Rolnik et al., 2017b). The primary aim of this thesis was to identify biomarkers that 
may be of value in screening for sPTB – measured at a similar early gestational age.  
Whilst there may be multiple aetiological pathways that lead to spontaneous 
preterm birth, these pathways appear to converge such that there is a final common 
process triggering labour. Given that these aetiological processes are often chronic, we 
hypothesised that it would be possible to identify alterations in protein abundance as 
early as 11-13+6 weeks’ gestation in pregnancies that go on to labour spontaneously. 
We therefore conducted a series of experiments designed to identify candidate protein 
markers and to validate the findings of these proteomic studies. 
The initial focus of this work was the development of a sensitive quantitative 
top-down analytical technique that would allow detailed assessment of the first 
trimester maternal serum proteome. The process needed a large dynamic range to be 
able to resolve both high and low abundance proteoforms (D'Silva et al., 2017). This 
approach was needed as traditional proteomic techniques remove high abundant 
proteins to resolve less abundant counterparts (Echan et al., 2005, Gong et al., 2006, 
Bellei et al., 2011). This traditional approach may remove other important species, 
which are bound to more highly abundant proteins such as albumin; this can therefore 
prevent accurate quantification of serum proteoforms.  
The methods used to resolve the serum proteome in this study were based on 
the physicochemical and structural characteristics of the constituent proteins, 
including solubility, hydrophobicity, molecular weight and isoelectric point. A series 
of optimisation techniques followed by comparative analyses were undertaken to 
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determine the most efficient and optimal method of sample handling/prefractionation, 
resolution and identification of native protein species. I was able to thus, establish a 
2DE/LC/MS/MS approach to resolve and identify native protein species from first 
trimester maternal serum (D'Silva et al., 2017). 
In addition to the various techniques tested to optimize efficient resolution of 
the native serum proteome, we also combined the top-down 2DE protocol with a 
highly sensitive staining and detection protocol, third dimension electrophoresis and 
deep imaging - as well as selective staining to assess phospho- and glycoprotein sub 
proteomes (i.e. proteoforms) (Gauci et al., 2013, Wright et al., 2014b, Wright et al., 
2014a). This enabled me to maximise extraction of data from each gel. In summary, I 
have developed a technique that can be routinely used for analysing the proteome of 
crude serum samples, that does not involve fractionation and therefore retains the 
native complement and stoichiometry of protein species, and fully enables quantitative 
analysis (D'Silva et al., 2017). 
Optimisation of this 2DE/LC/MS/MS method for examining the first trimester 
maternal serum proteome enabled further investigation and comparison of first 
trimester maternal protein profiles from pregnancies that subsequently delivered 
preterm (spontaneously) and those that delivered at term. In our second paper, we 
identified 30 proteoforms that were altered in the sPTB group in comparison to the 
full-term cohort. This included 9 phosphoproteins and 11 glycoproteins. Notably, key 
findings of this manuscript included identification of serum albumin, Vitamin D-
binding protein and Apolipoprotein A-1 across three different assessments: namely 
total protein profiles, as well as in the phosphoproteome and the glycoproteome 
(D'Silva et al., 2018).  
Several of the identified proteins were present in the 2DE gels as more than 
one proteoform, with MW and/or pI differing from the theoretical values that are based 
only on amino acid sequences. It is interesting to note that amongst the differentially 
abundant protein species, three (i.e. Alpha-1-antitrypsin, Vitamin D-binding protein, 
Apolipoprotein A-1) were found to be both phosphorylated and glycosylated. 
Complement C4-A was identified across total protein profiles and phospho analyses 
whilst Ig gamma-1 chain C region and Complement C3 were identified across total 
protein profiles and glyco analyses.  
Notably, this study included a heterogeneous group of women with diverse 
ethnic backgrounds and pregnancy characteristics. Most identified proteins were 
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involved in clinically relevant biological processes, including interrelated biological 
networks linked to regulation of the complement cascade and coagulation pathways, 
immune modulation, metabolic processes and cell signalling (D'Silva et al., 2018). 
To the best of our knowledge, this is the first study to investigate PTMs as early 
as the first trimester of pregnancy (D'Silva et al., 2018). The findings from this study 
suggested that these proteins had potential as important early biomarkers of sPTB and 
possible disease mediators. Extending to validation of the proteomic analyses, we 
selected four proteins of interest to be assessed in a larger cohort of patients. The four 
proteins (Alpha-1-antitrypsin, Vitamin D-binding protein, Alpha-1 beta-glycoprotein 
and Apolipoprotein A-1) were selected due to substantial changes in their abundance 
in the sPTB group when compared to the term cohort, as well as their association with 
other pregnancy complications including preterm birth (Madar et al., 2013, Sorensen 
et al., 2016, Feng et al., 2012, Timur et al., 2016).  
Western blot analysis confirmed increased abundance of Alpha-1-antitrypsin 
and Vitamin D-binding protein in sPTB cohort of the original sample set (n=10) and 
generally, the overall pattern of expression did reflect the observations from the initial 
2DE observations. Quantitative immunoblot analyses of the selected candidate 
proteins were also carried out to determine their expression levels in a larger 
independent cohort of women. The analysis determined that Vitamin D-binding 
protein decreased (p = 0.04) in the sPTB cohort when compared to the control. The 
reason for this shift in the trend of abundance and why the validation of Vitamin D-
binding protein does not fully correlate with our previous 2DE findings may well be 
because Vitamin D-binding protein was identified by total protein staining but also as 
clearly separate phospho- and glyco-proteoforms. Vitamin D-binding protein contains 
multiple phosphorylation sites as well as other PTM. It is likely that a one-dimensional 
immunodetection analysis, such as the western blotting protocol used here (Paper 3), 
would not have adequately resolved nor thus identified these critical proteoforms.  
However, analyses of the other three proteins did not demonstrate sufficient 
sensitivity or specificity to offer promise as screening tools for sPTB but may well 
require further testing in a larger population cohort, particularly with regard to specific 
proteoforms as opposed to (presumably) assessing the total complement of a given 
protein rather than specific species (i.e. using immunodetection methods such as 
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western and ELISA, without species-selective antibodies). There are several reasons 
why we may not have been able to validate apparent changes in protein abundance 
associated with subsequent onset of sPTB in the remaining three proteins examined in 
this study. This has been discussed in some detail in Paper IV. Thus, the predictive 
usefulness of the current potential biomarkers to detect subtypes of sPTB as well as 
other gestational disorders (e.g. preeclampsia) also warrants more detailed study. 
A strength of the 2DE technique employed throughout this thesis is its 
resolution of proteoforms. This led to one of the key results of this research: the 
detection of two differentially glycosylated isoforms - Vitamin D-binding protein and 
Alpha-1beta-glycoprotein whose abundance levels changed between women with 
sPTB and healthy pregnant women. Glycosylation is one of the most common and 
vital PTM involved in modifying protein function (Apweiler et al., 1999). It is 
therefore not surprising that so many proteins identified in this thesis research are 
glycoproteins. Amongst the identified glycosylated proteins were Complement C3 and 
Antithrombin-III in sPTB (D'Silva et al., 2018). Complement C3 has been extensively 
studied in the literature for its role in the innate immune response while Antithrombin-
III has been associated with the coagulation cascade (Regal et al., 2015, Ramalakshmi 
et al., 1995). Although traditionally viewed as separate entities, studies have suggested 
that functional relationships exist between coagulation and innate immunity and that 
exploration of these integrated systems may further develop our understanding of 
responses to tissue injury and subsequent inflammation (Delvaeye and Conway, 2009, 
Opal and Esmon, 2002). Despite its critical role in several disease mechanisms, the 
application of glycoproteomics to the discovery of biomarkers is still in its infancy. 
Significant improvements in technology will certainly advance this field rapidly in the 
coming years. 
 
Review of additional / recent research findings 
Since the inception of this project and completing the initial literature review that 
facilitated study design, a few additional research papers have been published which 
are relevant to this work. 
 
 
130 
 
Additional work on the inflammatory cascade/inflammation and infection 
Previous research has documented that obesity is related to chronic inflammation 
(Djelantik et al., 2012, Wise et al., 2010). To understand the effect of obesity on 
preterm birth, a study examined second trimester serum samples from obese women 
who delivered prematurely and obese women who delivered at term using regression 
tree techniques. The study found that soluble vascular endothelial growth factor 
receptor-3, soluble interleukin-2 (IL-2) receptor alpha-chain, and soluble tumour 
necrosis factor receptor 1 were associated to preterm birth in obese women 
(Wallenstein et al., 2016). The finding of these inflammatory biomarkers in this pilot 
study is generally consistent with previous work that implicates inflammatory 
mediators in the common pathways of preterm birth and obesity.  
Additional studies for single biomarkers 
Much research on the utility of single biomarkers such as alpha-fetoprotein, fFN, C-
reactive protein, IL-6 in the prediction of preterm birth has been done (Table 1.2). 
Increased levels of IL-6, but not pIGFBP1 in second trimester cervical secretions has 
been linked with threatened preterm labour and intact membranes (Brik et al., 2014). 
In another study, IL-6 and fFN in CVF have been suggested to be effective in the 
prediction of preterm delivery in symptomatic patients (Hadži-Lega et al., 2015). 
Using an IL-6 cut-off of 1305 pg/mL performed best in prediction of preterm delivery 
with sensitivity of 69.4% and specificity of 68.2%. A positive fFN test had an OR of 
6.4 (95% CI: 2.0 - 20.8) to deliver prematurely. The combination of both tests 
performed better than the individual tests.  
The same group conducted another study to determine the relationship between 
cervical length, fFN, phIGFBP-1, cytokines (IL-6, IL-2 receptor and TNF-α) and sPTB 
(which may have occurred up to 14 days from the point of sampling). The biochemical 
markers assessed were only moderately successful in the prediction of preterm 
delivery (Hadzi-Lega et al., 2015). Another study suggested alternative risk thresholds 
(less than 10 ng/mL and greater than 200 ng/mL) to improve the accuracy of fFN to 
define risk of sPTB for asymptomatic women with a short cervix (Abbott et al., 2015). 
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Table 1.2: Predictive accuracy for the different biomarkers of preterm birth (Lucaroni 
et al., 2017) 
*LR: likelihood ratio, OR: odds ratio 
Key 
proteins 
Author  Results  
fFN Boots et al., 
2014 
Sanchez-Ramos 
et al., 2009 
Delivery within 48 h: Sensitivity: 62% (43–68); 
specificity: 81% (74–86); LR+3.3 (95%CI 2.1–5); 
LR 0.47 (95%CI 0.29–0.76); DOR 7 (95%CI 3–17) 
Delivery within 7 days: Sensitivity: 79% (69–80); 
specificity: 79% (76–83); LR+3.6 (95%CI 3.1–4.3) 
LR 0.31 (95%CI 0.25–0.39) DOR 11.5 (95%CI 8–
16) 
Delivery within 7 days: Sensitivity: 76% (69–82); 
specificity: 82% (79–84); LR+4.2 (95%CI 3.5–5) 
LR 0.29 (95%CI 0.22–0.38); DOR: 14.4 (95%CI 
9.7–21.3) 
TNF- α Liu, 2015 
Conde-
Agudelo, 2011 
OR : 0.84 (95%CI 0.65–1.07) 
LR+: 3.9 (2.6–5.9); LR: 0.2 (0.1–0.4) (amniotic 
fluid) 
IL – 1 
IL – 6 
IL – 8  
IL – 18  
IFN – γ 
Hee, 2011 
Wu, 2013 
Hee, 2011 
Hee, 2011 
Liu, 2015 
LR+: 2.3 (0.8–5.7); LR: 0.6 (0.3–1.3) (amniotic 
fluid) 
OR : 0.98 (95%CI 0.72–1.33) 
LR+: 9.7 (3.2–29); LR: 0.2 (0.1–0.4) (amniotic 
fluid) 
LR+: 4.4 (1.4–15); LR: 0.7 (0.6–0.9) (serum) 
OR : 1.14 (95%CI 1.11–1.73) 
CRP Hee, 2011 
Wei, 2010 
LR+: 2.8 (1.5–5.4); LR: 0.6 (0.4–0.8) 
OR 1.53 (95%CI 1.22–1.90) (plasma) OR 7.85 
(95%CI 3.88–15.87) (amniotic fluid)  
MMP – 8 
MMP – 9  
Conde-
Agudelo, 2011 
Hee, 2011 
LR+: 40.0 (5.3–301.4); LR: 0.6 (0.4–0.9) 
LR+: 6.0 (0.9–41); LR: 0.8 (0.6–1.1) (urine) LR+: 
7.3 (1.1–50); LR: 0.4 (0.1–0.9) (plasma) 
phIGFBP-1 Conde-
Agudelo, 2015 
Hee, 2011 
Conde-
Agudelo, 2011 
Sensitivity: 38 (32–44); specificity: 77 (76–78); 
LR+: 1.6(1.3–2.0); LR: 0.8 (0.7–0.9) 
(cervicovaginal fluid) 
LR+: 5.7 (2.3–14); LR: 0.3 (0.1–0.9) 
Sensitivity: 38 (31–45); specificity: 58 (56–61); 
LR+: 0.9 (0.8–1.1); LR: 1.1 (1.0–1.2) (blood) 
PAPP-A Conde-
Agudelo, 2011 
Sensitivity: 11 (10–12); specificity: 93 (93–93); 
LR+: 1.6 (1.4–1.8); LR: 1.0 (0.9–1.0) (blood) 
Placental 
protein 13 
Conde-
Agudelo, 2011 
Sensitivity: 28 (17–43); specificity: 90 (86–93); 
LR+: 2.8 (1.6–5.0); LR: 0.8 (0.6–1.0) (blood) 
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Additional studies using multivariate models 
Various groups have made attempts to establish models for accurate prediction of 
preterm birth. These models, however, have only been effective in the symptomatic 
and high-risk asymptomatic populations. One such example is a model combining fFN 
and previous sPTB/PPRoM to predict sPTB in symptomatic women (Kuhrt et al., 
2016a). Another study by the same group has proposed combining fFN, cervical length 
and past obstetric history to predict sPTB in asymptomatic high-risk women (Kuhrt et 
al., 2016b). These models have been incorporated into an App (QUiPP) to determine 
a woman's risk of sPTB that is freely available online. 
In a more recent study, the QUiPP App was used to identify those at risk of 
sPTB, relative to a treat‐all strategy in symptomatic women at 24 to 29+6 weeks' 
gestation. The study showed that the QUiPP App can accurately guide management at 
risk thresholds for sPTB of 1%, 5% and 10%. While this study provides useful insight, 
this approach may not be practical in all situations as the model assumes that every 
clinician and patient accept the findings of the App. Furthermore, data from only a 
minority of women was included to develop the App and this needs to be tested in an 
external dataset to test its utility (Watson et al., 2017) 
Another European group constructed two modified prediction models for 
assessment of individualized risk and accurate prediction of preterm birth (within the 
next 48hr, and before a 32 completed weeks of gestation) (Mailath-Pokorny et al., 
2015). The models incorporated the presence of PPRoM and/or vaginal bleeding, 
cervical length, gestational age, fFN, and serum CRP. Development of such models 
can be used to counsel patients and might help to individualize patient care. 
Nevertheless, future studies are necessary to investigate the external validity of the 
models and whether additional validated markers should be incorporated. 
Nomograms are models designed to help clinical decision making when 
assessing patient risk and outcome (Dabi et al., 2017, Kattan et al., 2004). A nomogram 
with a high positive predictive value and low false-negative rate was developed for 
preterm delivery (Allouche et al., 2011). Prospective validation of the model was 
carried out by another group to demonstrate the efficiency of the model in predicting 
individual risk of preterm delivery. The tested nomogram assessed the probability of 
delivery within 48 hours and the probability of delivery before 32 weeks of gestation. 
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Several parameters including number of fetuses, cervical length was used to calculate 
individual scores for the risk of delivery. The authors conclude that a threshold set at 
15% would help minimize the risk of preterm deliveries in singleton pregnancies and 
should reduce unnecessary, costly and stressful in utero transfer (Dabi et al., 2017). 
 
Additional work about post-translational modifications  
As noted previously, elevated levels of phIGFBP-1 in mid-trimester cervical secretions 
have been reported to be a good predictor of preterm birth in symptomatic women 
(Kekki et al., 2001, Kurkinen-Raty et al., 2001). Several other groups have confirmed 
these findings and have shown phIGFBP-1 to be advantageous when compared to 
cervicovaginal fFN (Goyal et al., 2016, Tripathi et al., 2016). A recent systematic 
review and meta-analysis has demonstrated the ability of cervical phIGFBP-1 to 
identify patients with an episode of preterm labour who will not deliver within 48 hours 
(Conde-Agudelo and Romero, 2016). Currently, many countries including Canada, 
United Kingdom, Germany, France, Italy, Australia and New Zealand are using 
cervical phIGFBP-1 test for predicting predict preterm birth in the symptomatic cohort. 
Nevertheless, the overall predictive value of cervical phIGFBP-1 for identification of 
preterm birth has been challenged in some reports.  
 
Common findings 
A large-scale bottom-up proteomic analysis was carried out to identify biomarkers 
associated with preterm birth using first trimester plasma samples (Lynch et al., 2016). 
The study identified complement factors B and H and the coagulation factors IX and 
IX ab as the highest-ranking proteins distinguishing cases of preterm birth from term 
controls. The top three pathways associated with preterm birth were the complement 
cascade, the immune system, and the clotting cascade. As shown in Paper III, the 
results are consistent with previous investigations suggesting that inflammatory and 
immune related events in early pregnancy are part of the pathogenic mechanisms of 
sPTB. Our study demonstrated elevated levels of complement factors B and H in the 
sPTB cohort when compared to the full-term cohort (D'Silva et al., 2018). These 
complement factors are likely elevated as part of an effort to self-regulate in response 
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to inflammatory events originating in the placenta in early pregnancy (D'Silva et al., 
2018). My study identified proteins associated with the complement and clotting 
pathways in women that had no signs of intra-amniotic infection and delivered 
spontaneously preterm, implying that activation of these pathways individually or in a 
combined manner in the first trimester is prompted by inflammatory events that may 
not necessarily be infectious in origin.  
 
First trimester prediction and prevention of preterm birth 
The first trimester of pregnancy provides a valuable opportunity for screening and 
preventative intervention, enabling critical, earlier streamlining of care. It is equally 
important to identify women at low risk for adverse pregnancy outcomes – as these 
women can be offered simpler forms of supervision through pregnancy without over-
medicalization of their care. Despite the vast amount of knowledge available, the 
clinical utility of biomarkers and risk assessments for accurate prediction of adverse 
pregnancy outcomes is questionable.  
Nonetheless, in the last decade, first trimester tests to identify women at risk of 
developing adverse pregnancy complications including preeclampsia, gestational 
diabetes and fetal growth restriction has attracted much attention from research teams. 
Most of the research directed toward screening high-risk women relied upon the 
hypothesis that adverse pregnancy outcome was related to poor placentation. One of 
the strongest examples that illustrates the success of first trimester screening is the 
ASPRE trail; >90% of preeclampsia cases leading to delivery <34 weeks were 
predicted through a multivariate 11-13+6-week screening test. Prophylactic prescription 
of aspirin then prevented 80% of disease affecting this cohort (Rolnik et al., 2017a). 
Current screening algorithms have poor predictive efficacy for preterm birth, 
particularly for nulliparous women. For several years, great effort has been devoted to 
study several proteins including PAPP-A, placental growth factor and CRP. Although 
reduced PAPP-A levels have been observed in women who deliver <34 weeks 
spontaneously, its predictive capacity is no greater than maternal characteristics. In an 
unselected population, the situation is even poorer, with no predictive capacity for a 
variety of proposed first trimester biomarkers and ultrasound measurements. Hence, 
135 
 
there is a need for large prospective studies to ascertain the combination of different 
biochemical markers for improvement of this condition. 
 
Difficulties of using proteomics to investigate / identify novel serum markers for 
T1 screening  
MS-based proteomic analysis is a powerful tool for identifying disease specific 
proteins in sera and to aid in understanding complex molecular networks and 
pathways. Many studies have successfully utilised various proteomic methods in order 
to determine some aspects of the underlying molecular and functional pathways 
associated with preterm birth. However, there are many discrepancies in the reported 
results. A major reason for these possible discrepancies in protein data relates to the 
proteomic technology selected. Even in studies utilising similar methodologies, 
different research groups and laboratories have also found variations in the identified 
proteins or peptides of interest.  
These differences could be due to variabilities introduced during sample 
collection and processing (time and temperature), sample storage and number of freeze 
thaw cycles introduced (McLerran et al., 2008, Lygirou et al., 2015). In order to reduce 
experimental variability, it is essential for all case and control samples to be handled 
in the exact same manner throughout the study (Timms et al., 2007). Even minor 
differences in specimen handling could impact the stability of protein species and 
eventually affect reproducibility of the experiment (Enroth et al., 2016, Tuck et al., 
2009, Guest and Rahmoune, 2017). There is a need for stringent standard operating 
procedures specimen collection and handling to facilitate proteomic work for 
biomarker discovery and subsequent validation. One of the advantages of our work 
was that all samples had been managed through a formal clinical quality assurance 
process and both subjects and controls were managed in the same way. 
Traditional 2DE techniques do not allow precise analysis of co-migrating 
spots; other validation techniques must be applied to confirm the presence of and 
quantitative changes in protein species of interest. Specific immuno-detection in 
western blot analysis provides a semi-quantitative assessment of changes in protein 
species. Multiple Reaction Monitoring (MRM), a promising new MS quantitation 
technique, uses triple quadrupole mass spectrometers to target and quantify proteins 
of interest, (Anderson and Hunter, 2006). This approach enables some degree of 
enhanced specificity and does not suffer from the same extent of issues related to cross-
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reactivity with other molecules, and hence may likely replace some immunoassay 
measurements in the near future.  
Nevertheless, MRM-MS presents its own challenges. One major issue with 
conducting MRM-MS is its sensitivity. The MS signal produced by a peptide or protein 
is negatively affected by the complexity of the sample. To overcome this, complex 
samples such as serum would require steps such as fractionation to reduce its 
complexity or enrichment for targeting specific proteins prior to MRM-MS analysis 
(Mehaffy et al., 2017). This step introduces experimental variability and further 
decreases throughput. The results of MRM-MS are dependent on effective coverage 
i.e. the more chosen peptides, the better the coverage. Typically, three peptides unique 
to the full target protein is preferred, adding to the costs of the assay (Liebler and 
Zimmerman, 2013). MRM-MS is also limited to the analysis of one sample at a time, 
and the only way of substantially increasing throughput is to install multiple mass 
spectrometers, which represents a major capital expense (Parker and Borchers, 2014).  
Multiple proteins were identified from each of the 2D gel spots examined in 
this study. Until quite recently, it has been common to assume in 2DE analysis that 
only a single proteoform is present (or identifiable) within a single gel spot. If multiple 
proteoforms are present, and differential regulation of at least one species result in 
apparent changes on gel images, which species is responsible? The phenomenon of 
protein co-migration, where multiple proteins are present and identified within a single 
gel spot, has not been well discussed in the older 2DE literature. Our study employed 
refinement approaches (3DE and deep imaging) to further resolve highly abundant and 
associated species as an approach to address the issue of co-migration. The large 
amount of protein data derived from MS analysis of each gel spot in the current study 
required its own dataset filtering method, similar to the large volume of 2D gel data 
initially leading to those spots.  
Although conveniently available, human serum is one of the most challenging 
biospecimens to work with. The valuable information obtainable from serum probably 
closely reflects the specific and changing physiological and pathological states of the 
whole human body. Nevertheless, the two major complications in discovery 
proteomics of serum is that the dynamic range of proteins complicates the 
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identification of candidate proteoforms. Another important question concerns sample 
size and the associated biological disparity within any cohort. 
Most serum proteome studies are carried out by comparing protein profiles in 
pooled sample sets from healthy and diseased individuals. This approach has two 
major disadvantages: a) it does not account for individual variation and b) it can lead 
to false positive and false negative results as some biomarkers display low inter-
individual variation while others exhibit high inter-individual variation. It is therefore 
imperative to take biological variation into account at, preferentially, an early point in 
the biomarker discovery pipeline. For this very reason, the proteomic and 
immunoassay methods employed in this thesis involved analysis of individual samples 
in technical replicates (minimum of triplicates).  
Only a limited number of studies rely on the quantitative proteomic analysis of 
a number of individual samples, which gives some insight into biological variation, 
and also insight into how the scientific method is bypassed in many studies that seek 
high throughput over high quality data. In any case, follow-up studies, for 
quantification of potential candidates by well-designed orthogonal methods (e.g.  
immuno assays or multiplexed MRM) are necessary to ensure that selected candidate 
biomarker proteins can be fully validated. For effective biomarker discovery, 
collection and storage of high-quality samples is critical. Furthermore, various 
environmental influences may affect the serum proteome due to which accurate 
disease-specific factors are difficult to identify by simply comparing different 
individuals. Therefore, using proteomic methods to identify sensitive biomarkers 
specific to preterm birth has been challenging. To screen for preterm birth-related 
proteins, in this study we obtained paired sera from patients that delivered 
spontaneously <37 weeks’ gestation and those that delivered at full-term >37 weeks’ 
gestation.  
Although the sample size in our initial study was small, we were able to obtain 
high quality well characterised sPTB samples after applying stringent inclusion and 
exclusion criteria. To date, many studies have investigated the serum proteome, 
attempting to characterise the protein expression within this complex biological fluid 
using a variety of proteomic methodologies. However, the choice of methods 
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employed to address this complex dynamic sample has not proven to be effective in 
reproducing the results across different populations.  
Traditionally, analyses using 2DE posed challenges including low dynamic 
range of proteins and the visualization of faint protein spots (i.e. of low abundance) 
resolved on 2DE gels (Magdeldin et al., 2014). To overcome these issues, my study 
capitalized on further refinement of an established sensitive 2DE method that was not 
only able to resolve native serum proteins but was able to further resolve proteoforms 
by a 3DE approach enabling detection of co-migrating species. Furthermore, a deep 
imaging protocol developed for serum involved excision of a range of selected highly 
abundant proteins after an initial round of imaging, to enable the visualisation of lower 
abundance proteins. I was thus able to develop an efficient, sensitive and reproducible 
technique that substantially improved the quantitative protein profiling of native 
human serum, and that should prove widely applicable to a range of comparable 
sample types including plasma and urine. 
 
Difficulties in assessing PTMs 
Due to its complex and diverse nature, PTM identification continues to remain a 
challenge in the field of proteomics. To date, more than 300 PTMs known to occur 
physiologically in humans have been identified (Liddy et al., 2013, Witze et al., 2007). 
Typically, PTM analysis is based on single peptide species. PTM identification is 
further complicated as they generate complex fragmentation patterns in tandem mass 
spectrometry (Wang et al., 2014). Several groups have made attempts to develop 
methods for identification of common protein PTMs (phosphorylation and 
acetylation); however, identification of the uncommon protein PTMs (glypiation, 
sumoylation, cholesteroylation) continues to remain a challenge and these methods 
cannot be automated (Basak et al., 2016).  
Furthermore, for the methods that can be automated, prior enrichment such as 
immunoprecipitation is necessary. Affinity based enrichment techniques are typically 
employed for low abundance PTMs. However, affinity based enrichment methods are 
only applicable for known well-characterised protein targets and, furthermore can 
cause concomitant removal of non-targeted protein species (Xie et al., 2009). The 
enriched proteins are then analysed by downstream methods like western blot with a 
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target PTM antibody (after being separated by SDS-PAGE) or by mass spectrometry 
to determine if a protein of interest is post-translationally modified (Farley and Link, 
2009, Young et al., 2010).  
Choosing an appropriate method is critical to study low abundance PTM 
modifications. PTM site determination is very dependent on the particular peptide 
sequence (Parker CE, 2010). A further challenge in PTMs is not only to accurately 
identify them but also to validate them due to lack of commercially available PTM 
specific antibodies (Tyther and Jenkins, 2011). Additionally, previous research has 
shown that PTM modifications may block the antibody binding site on the protein of 
interest, generating false negative results (Hattori and Koide, 2018).  
One of the most common methods for identifying PTM is tandem mass 
spectrometry combined with searching a protein sequence database (Guthals and 
Bandeira, 2012). This method has several drawbacks, as the user needs to specify all 
anticipated modifications before the search engine feeds this information considering 
various combinations of these modifications for all peptide sequences. If several 
potential modifications are considered, the search can take much longer than the data 
acquisition, creating a bottleneck in high-throughput analysis (Savitski and Savitski, 
2010). 
Various targeted approaches employing selected reaction monitoring/multiple 
reaction monitoring (SRM/MRM) have been employed for the study of several 
enzymatic and non-enzymatic PTMs in cardiac proteomic research (Holman et al., 
2013, Gianazza and Banfi, 2018). Further research on development of techniques to 
accurately identify and quantify PTM for preterm birth in clinical samples would help 
to determine whether a pathway is critically modulated in the disease state and how 
this activity is affected by treatment/intervention. Currently the community is still at 
the stage of proof of principle investigations of these concepts (Lima et al., 2018).  
My study applied MS-based proteomics after resolving the serum proteome 
using highly sensitive phosphor- and glycol-staining approaches as an initial screen to 
identify globally altered proteoforms in the maternal serum (as discussed in paper 2). 
Though advantageous as a screening approach, bottom-up MS-based proteomics 
provide tens of thousands of sites, raising the question of their biological relevance, 
and imposing the challenge of how to select a very small number of relevant sites from 
the vast number of hits generated, and how to perform functional follow-up on these. 
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At a minimum, data collected through this approach requires validation by orthogonal 
methods before any statement about their validity can be made. Obvious prioritization 
criteria used in this thesis include high identification and quantification accuracy 
(based on mascot scores, unique peptides and sequence coverage). 
In this thesis, a western blot approach was used as a validation tool to quantify 
candidate proteins - namely Alpha-1-antitrypsin, Vitamin D-binding protein, Alpha-1 
beta-glycoprotein and Apolipoprotein A-1 in a larger independent cohort of women. 
The candidate proteins were found to be present as phosphorylated and glycosylated 
proteoforms. However, most antibodies used in classical immunodetection approaches 
such as western blot do not account for specific proteoforms (i.e. phosphorylation and 
glycosylation).  
Although the sample size in our validation study was small (i.e. 44 sPTB and 
44 matched controls), the western blot results obtained after extensive optimisation 
were highly reproducible. As emerging evidence suggests a role for combinations of 
PTMs in the identification of disease markers, (Gajjala et al., 2015, Duan and Walther, 
2015) it likely would be valuable to investigate other phosphorylated and glycosylated 
proteoforms from the original list of identified proteins (Table 4, paper 3). For 
example, phosphorylated vitronectin was found to be significantly increased in the 
sPTB cohort by 2-fold (D'Silva et al., 2018). 
Vitronectin is involved in immune defence and enhances the inflammatory 
process during infection (Hadders et al., 2012). Previous studies have shown a 
correlation between vitronectin and preeclampsia demonstrating an increase in the 
level of vitronectin in placenta and plasma of patients with preeclampsia, consistent 
with my findings (Shen et al., 2013, Blumenstein et al., 2009, Balci Ekmekci et al., 
2015). As both preterm birth and preeclampsia are apparently related via 
inflammation, it would be worthwhile examining whether phosphorylated vitronectin 
is involved in the mechanistic pathway associated with preterm delivery.  
As PTMs are so diverse and serve different purposes in cellular processes, 
studies must focus their attention on identifying different combination patterns of 
PTMs in order to understand their roles in disease mechanisms and biological 
outcomes. Further research into developing monoclonal antibodies that recognize 
biologically important PTMs is desirable. 
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It is impractical to hope that established immunoassays (based on antibodies 
primarily targeting canonical proteoforms) can validate more than a small fraction of 
the proteoforms / PTM sites being identified. Whilst MS-based proteomic techniques 
such as SRM/MRM have proven to be successful in identifying and measuring specific 
post-translationally modified proteoforms, the limitation associated with these 
methods should be carefully considered (Percy et al., 2013). It is, however, important 
to recognise that these techniques have enormous potential to revolutionize biomarker 
measurement techniques (Ozcan et al., 2017, Cordeiro et al., 2017).  
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Future Directions  
The most immediate aim of future investigation is to quantitatively validate other ’hits’ 
arising from this first trimester maternal serum proteome investigation. A 
multidisciplinary approach to preterm birth research should be considered, as the 
molecular pathophysiology, aetiology and symptomatology are highly complex and 
poorly understood. Combining an omics-based Systems Biology approach to the 
investigation of pathophysiological process underlying diseased states will bring about 
more personalised, predictive and preventive medical care. 
Considerable effort is being made to integrate the large datasets generated from 
each of the complementary omic methods (i.e. genomics, transcriptomics, proteomics, 
epigenetics, metabolomics, glycomics) to understand disease mechanisms. Due to the 
multifactorial nature of preterm birth, it is very likely that a combination of markers 
will be necessary to effectively detect this condition. To look for such “fingerprints” 
of preterm birth and understand its pathophysiology, will require not only in-depth 
proteomic profiling, but also linkage of the proteomic data to its genomic expression 
and sophisticated bioinformatics tools for complex data analysis and pattern 
recognition.  
Furthermore, it would be interesting to study the epigenetic modifications 
(DNA methylation and histone modifications etc.) associated with preterm birth. 
Epigenetic modifications and genetic mechanisms work hand in hand to regulate 
transcriptional activity. These epigenetic changes can precede disease pathology and 
thus could prove to be prognostic indicators for risk of preterm birth and may also 
serve as indicators of disease progression. This may provide the potential for 
developing a minimally-invasive prognostic or screening tool for preterm birth. 
More specifically, one of the challenges I encountered in this study included 
finding commercially available monoclonal antibodies that were tested in serum. In 
order to test other candidate proteins, it would be worthwhile investing resources to 
raise in-house antibodies (with high specificity and sensitivity) against a select group 
of candidate proteins. An ideal candidate would not only show a change in protein 
abundance but would also have a small standard deviation – allowing more effective 
discrimination between control and preterm groups. 
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As my study identified significantly altered levels of VDBP, future work 
should include use of a target-based approach (such as MRM) to validate this finding 
in a larger independent cohort. Ideally this would be tested in a population-based 
sample so that relative distributions in control and preterm cases can be calculated, 
which will allow the development of likelihood ratios to describe the risk of preterm 
delivery. This type of population would also allow the efficacy of this screening tool 
(in terms of sensitivity and specificity) to be assessed. As most of the proteoforms 
identified in my study were linked to the inflammation cascade, it would be worthwhile 
reviewing whether these markers are also significantly altered in women who have 
PPRoM later in their pregnancy. There are very few identified biomarkers for this 
condition – which causes significant morbidity. 
While this study only focussed on first trimester samples and did not include 
serial evaluation of markers, the identification of inflammatory biomarkers as early as 
the first trimester of pregnancy suggests that serial sampling could be beneficial for 
two reasons. First, to follow subjects with symptoms of preterm labour and determine 
when interventions such as antenatal steroids should be administered and second to 
determine mechanisms by which these biomarkers impact outcomes.  
There are challenges in establishing a reliable minimally-invasive diagnostic 
method. Ideal requirements include high sensitivity and specificity, satisfactory 
positive and negative predictive values for detecting sPTB, and for the test to be cost 
effective and readily available. Additional considerations when developing a reliable 
and valid diagnostic or screening tool include the need to account for natural individual 
variations within the population. Nevertheless, rapid advances in proteomic 
technology will build upon the knowledge currently available to understand the 
molecular events and pathways that lead to the initial implantation and consequent 
development of disease. The introduction of advanced protein analysis platforms into 
clinical trial usage for generating biomarker profiles will offer improved diagnostic 
and prognostic efficacy. 
Without a doubt, proteomic technologies are providing valuable information to 
further understand the molecular biochemistry behind the initiation of preterm labour, 
as evidenced by the steadily expanding body of literature. There is an urgent need for 
improved clinically well-characterised samples (both biological tissues and fluids) and 
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joint collaborations with obstetricians and scientists to appropriately characterise 
different subtypes of preterm birth.  
The proteins identified from amniotic fluid, serum, plasma, urine and CVF are 
all contributing significant information to the pathway puzzles that are the biology of 
preterm birth. It is evident that with advancement of proteomic technologies, new 
molecules will continually be found to have specific associations with aspects of 
functional networks underlying preterm birth. 
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Summary 
In summary, the proteomic methodology utilised in this thesis has enabled 
identification of dysregulated protein species and post translational modifications that 
may have future application in the diagnosis of preterm birth. Finding differences in 
key molecular processes has pointed toward the likely disruption of pathways 
associated with the complement cascade, immune modulation, metabolic processes 
and cell signalling all being able to play roles in the pathogenesis of spontaneous 
preterm birth.  
There are still so many uncertainties about our knowledge of prematurity that 
this will remain a critical field for research for many years to come. A multidisciplinary 
approach that not only involves clinicians and scientific researchers, but also brings 
together complementary omic-based methods will be critical to understanding these 
underlying disease processes. Our ultimate aim should be to devise a more 
personalised, predictive, preventive and effective healthcare model for this challenging 
disease. 
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